Method for detecting variant nucleic acids
The method enhances the detection of genomic mutations in single cells by using mutation-specific probes and gap filling processes to generate accurate libraries for sequencing, addressing the limitations of current integration methods.
Patent Information
- Application Number
- PCT/US2026/026885
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2025-05-06
- Filing Date
- 2026-05-06
- Publication Date
- 2026-11-12
AI Technical Summary
Current methods for integrating genetic mutation analysis with transcriptomics lack sensitivity and accuracy, particularly in the analysis of single cells.
A method involving the use of mutation-specific probes that hybridize to target nucleic acids, incorporate reversible terminator nucleotides, and undergo a gap filling process to generate libraries of variant nucleic acids, which are then sequenced and analyzed using barcoded probes to enhance detection accuracy.
Improves the sensitivity and accuracy of detecting genomic mutations in single cells by reducing false positives and enhancing the identification of variant nucleic acids.
Smart Images

Figure US2026026885_12112026_PF_FP_ABST
Abstract
Description
[0001] Attorney Ref. No. 00B206.1727
[0002] METHODS FOR DETECTING VARIANT NUCLEIC ACIDS CROSS-REFERENCE TO RELATED APPLICATIONS
[0003] This application claims priority to U.S. Patent Application No. 63 / 800,821, filed May 6, 2025, the contents of which is incorporated by reference herein in its entirety.
[0004] FIELD
[0005] The present disclosure relates to methods, kits and systems for detecting variant nucleic acids in single cells.
[0006] BACKGROUND
[0007] The analysis of genetic mutations is useful in understanding complex biological systems and the pathology of complex diseases. In particular, the analysis of genetic mutations has facilitated the identification of genes involved in growth and development, as well as identifying the causes and progression of a wide variety of diseases, including cancer. Further, single cell analysis of genetic mutations in combination with transcriptome analysis provides valuable insights into development and disease. For example, such information can be used in determining the effect genetic mutations have on gene expression in a single cell, the progression of cancer, mapping cellular heterogeneity in diseased and healthy tissues and to gain a better understanding of natural biological processes. However, current methods that integrate genetic mutation analysis with transcriptomics lack sensitivity and accuracy.
[0008] Accordingly, there remains a need in the art for improved methods for the detection of genomic mutations in combination with transcriptomics.
[0009] SUMMARY
[0010] The purpose and advantages of the disclosed subject matter will be set forth in and are apparent from the description that follows, as well as will be learned by practice of the disclosed subject matter. Additional advantages of the disclosed subject matter will be realized and attained by the devices particularly pointed out in the written description and claims hereof, as well as from the appended drawings.
[0011] To achieve these and other advantages and in accordance with the purpose of the disclosed subject matter, as embodied and broadly described, the disclosed subject matter
[0012] 516578835.1 1Attorney Ref. No. 00B206.1727
[0013] provides for methods for generating libraries comprising a variant of a target nucleic acids and methods detecting variants of nucleic acids in single cells.
[0014] In certain embodiments, a method for generating a library comprising a variant of a target nucleic acid includes (a) providing a plurality of cells or nuclei, (b) contacting the plurality of cells or nuclei with at least one mutation-specific probe that hybridizes to a target nucleic acid, wherein the mutation-specific probe comprises a gap of at least one nucleotide and / or generates a gap of at least one nucleotide upon hybridization to the target nucleic acid and (c) performing a gap filling process. In certain embodiments, the gap filling process comprises (i) contacting the mutation-specific probe hybridized to the target nucleic acid with reversible terminator nucleotides to incorporate a reversible terminator nucleotide comprising a blocking group into the gap of the mutation-specific probe or the gap generated by hybridization of the mutation-specific probe to the target nucleic acid, (ii) removing the blocking group from the reversible terminator nucleotide incorporated into the mutationspecific probe and (iii) ligating the mutation-specific probe to generate a gap filled mutationspecific probe. In certain embodiments, the method further includes generating a target nucleic acid-specific library comprising the gap filled mutation specific probe.
[0015] In certain embodiments, a method for generating a library comprising a variant of a target nucleic acid includes (a) providing a plurality of cells or nuclei, (b) contacting the plurality of cells or nuclei with at least one mutation-specific probe that hybridizes to a target nucleic acid, wherein the mutation-specific probe comprises a gap of at least one nucleotide and / or generates a gap of at least one nucleotide upon hybridization to the target nucleic acid, (c) performing a gap filling process, where the gap filling process comprises: (i) contacting the mutation-specific probe hybridized to the target nucleic acid with reversible terminator nucleotides to incorporate a reversible terminator nucleotide comprising a blocking group into the gap of the mutation-specific probe or the gap generated by hybridization of the mutationspecific probe to the target nucleic acid, (ii) removing the blocking group from the reversible terminator nucleotide incorporated into the mutation-specific probe and (iii) ligating the mutation-specific probe to generate a gap filled mutation-specific probe, (d) contacting the cells or nuclei comprising the gap filled mutation-specific probes, wherein each of the particles is coupled to a polynucleotide comprising a barcode; (e) partitioning individual particles of the plurality of particles and the cells or nuclei comprising the gap filled mutation-specific probes into compartments, (f) incorporating the barcode of the polynucleotide into the gap filled mutation-specific probes to generate barcoded target nucleic acids, (g) combining all or a subset of the barcoded target nucleic acids to generate pooled barcoded nucleic acids and (i)
[0016] 516578835.1 2Attorney Ref. No. 00B206.1727
[0017] generating a target nucleic acid-specific library comprising the barcoded transcript-specific nucleic acids from the pooled barcoded nucleic acids. In certain embodiments, the method further includes sequencing all or a subset of the barcoded target nucleic acids in the target nucleic acid-specific library to identify one or more variants of the target nucleic acids.
[0018] In certain embodiments, a method for generating a library comprising a variant of a target nucleic acid includes (a) providing a plurality of cells or nuclei, (b) contacting the plurality of cells or nuclei with at least one mutation-specific probe that hybridizes to a target nucleic acid, wherein the mutation-specific probe comprises a gap of at least one nucleotide and / or generates a gap of at least one nucleotide upon hybridization to the target nucleic acid, (c) performing a gap filling process, where the gap filling process comprises: (i) contacting the mutation-specific probe hybridized to the target nucleic acid with reversible terminator nucleotides to incorporate a reversible terminator nucleotide comprising a blocking group into the gap of the mutation-specific probe or the gap generated by hybridization of the mutationspecific probe to the target nucleic acid, (ii) removing the blocking group from the reversible terminator nucleotide incorporated into the mutation-specific probe and (iii) ligating the mutation-specific probe to generate a gap filled mutation-specific probe, (d) contacting the cells or nuclei comprising the gap filled mutation-specific probes with a plurality of transcriptome-specific probes, (e) contacting the cells or nuclei comprising the gap filled mutation-specific probes and the transcriptome-specific probes with a plurality of particles, wherein each of the particles is coupled to a polynucleotide comprising a barcode, (f) partitioning individual particles of the plurality of particles and the cells or nuclei comprising the gap filled mutation-specific probes and the transcriptome-specific probes into compartments, (g) incorporating the barcode of the polynucleotide into the gap filled mutationspecific probes to generate barcoded target nucleic acids and incorporating the barcode of the polynucleotide into the transcriptome-specific probes to generate barcoded transcript-specific nucleic acids in the compartments, wherein the barcode of the barcoded target nucleic acids and the barcode of the barcoded transcript-specific nucleic acids present in a single compartment comprise the same nucleotide sequence, (h) combining all or a subset of the barcoded target nucleic acids and the barcoded transcript-specific nucleic acids from the compartments to generate pooled barcoded nucleic acids and (i) generating a target nucleic acid-specific library comprising the barcoded transcript-specific nucleic acids from the pooled barcoded nucleic acids. In certain embodiments, the method further includes sequencing all or a subset of the barcoded target nucleic acids in the target nucleic acid-specific library to identify one or more variants of the target nucleic acids. In certain embodiments, the method further
[0019] 516578835.1 3Attorney Ref. No. 00B206.1727
[0020] includes generating a transcript-specific library comprising the barcoded transcript-specific nucleic acids from the pooled barcoded nucleic acids. In certain embodiments, the method further includes sequencing all or a subset of the barcoded transcript-specific nucleic acids in the target nucleic acid-specific library.
[0021] In certain embodiments, a method for identifying a variant of a target nucleic acid includes (a) providing a plurality of cells or nuclei, (b) contacting the plurality of cells or nuclei with at least one mutation-specific probe that hybridizes to a target nucleic acid, wherein the mutation-specific probe comprises a gap of at least one nucleotide and / or generates a gap of at least one nucleotide upon hybridization to the target nucleic acid and (c) performing a gap filling process. In certain embodiments, the gap filling process comprises (i) contacting the mutation-specific probe hybridized to the target nucleic acid with reversible terminator nucleotides to incorporate a reversible terminator nucleotide comprising a blocking group into the gap of the mutation-specific probe or the gap generated by hybridization of the mutationspecific probe to the target nucleic acid, (ii) removing the blocking group from the reversible terminator nucleotide incorporated into the mutation-specific probe and (iii) ligating the mutation-specific probe to generate a gap filled mutation-specific probe. In certain embodiments, the method further includes generating a target nucleic acid-specific library comprising the gap filled mutation specific probe.
[0022] In certain embodiments, a method for identifying a variant of a target nucleic acid includes (a) providing a plurality of cells or nuclei, (b) contacting the plurality of cells or nuclei with at least one mutation-specific probe that hybridizes to a target nucleic acid, wherein the mutation-specific probe comprises a gap of at least one nucleotide and / or generates a gap of at least one nucleotide upon hybridization to the target nucleic acid, (c) performing a gap filling process, where the gap filling process comprises: (i) contacting the mutation-specific probe hybridized to the target nucleic acid with reversible terminator nucleotides to incorporate a reversible terminator nucleotide comprising a blocking group into the gap of the mutationspecific probe or the gap generated by hybridization of the mutation-specific probe to the target nucleic acid, (ii) removing the blocking group from the reversible terminator nucleotide incorporated into the mutation-specific probe and (iii) ligating the mutation-specific probe to generate a gap filled mutation-specific probe, (d) contacting the cells or nuclei comprising the gap filled mutation-specific probes, wherein each of the particles is coupled to a polynucleotide comprising a barcode, (e) partitioning individual particles of the plurality of particles and the cells or nuclei comprising the gap filled mutation-specific probes into compartments, (f) incorporating the barcode of the polynucleotide into the gap filled mutation-specific probes to
[0023] 516578835.1 4Attorney Ref. No. 00B206.1727
[0024] generate barcoded target nucleic acids, (g) combining all or a subset of the barcoded target nucleic acids to generate pooled barcoded nucleic acids, (i) generating a target nucleic acidspecific library comprising the barcoded transcript-specific nucleic acids from the pooled barcoded nucleic acids and (j) sequencing all or a subset of the barcoded target nucleic acids in the library to identify one or more variants of the target nucleic acids.
[0025] In certain embodiments, a method for identifying a variant of a target nucleic acid includes (a) providing a plurality of cells or nuclei, (b) contacting the plurality of cells or nuclei with at least one mutation-specific probe that hybridizes to a target nucleic acid, wherein the mutation-specific probe comprises a gap of at least one nucleotide and / or generates a gap of at least one nucleotide upon hybridization to the target nucleic acid, (c) performing a gap filling process, wherein the gap filling process comprises: (i) contacting the mutation-specific probe hybridized to the target nucleic acid with reversible terminator nucleotides to incorporate a reversible terminator nucleotide comprising a blocking group into the gap of the mutationspecific probe or the gap generated by hybridization of the mutation-specific probe to the target nucleic acid, (ii) removing the blocking group from the reversible terminator nucleotide incorporated into the mutation-specific probe and (iii) ligating the mutation-specific probe to generate a gap filled mutation-specific probe, (d) contacting the cells or nucleic comprising the gap filled mutation-specific probes with a plurality of transcriptome-specific probes, (e) contacting the cells or nuclei comprising the gap filled mutation-specific probes and the transcriptome-specific probes with a plurality of particles, wherein each of the particles is coupled to a polynucleotide comprising a barcode, (f) partitioning individual particles of the plurality of particles and the cells or nuclei comprising the gap filled mutation-specific probes and the transcriptome-specific probes into compartments, (g) incorporating the barcode of the polynucleotide into the gap filled mutation-specific probes to generate barcoded target nucleic acids and incorporating the barcode of the polynucleotide into the transcriptome-specific probes to generate barcoded transcript-specific nucleic acids in the compartments, where the barcode of the barcoded target nucleic acids and the barcode of the barcoded transcript-specific nucleic acids present in a single compartment comprise the same nucleotide sequence, (h) combining all or a subset of the barcoded target nucleic acids and the barcoded transcriptspecific nucleic acids from the compartments to generate pooled barcoded nucleic acids, (i) generating a target nucleic acid-specific library comprising the barcoded target nucleic acids from the pooled barcoded nucleic acids, (j) generating a transcript-specific library comprising the barcoded transcript-specific nucleic acids from the pooled barcoded nucleic acids and (k) sequencing all or a subset of the barcoded target nucleic acids in the library to identify one or
[0026] 516578835.1 5Attorney Ref. No. 00B206.1727
[0027] more variants of the target nucleic acids.
[0028] In certain embodiments, the method further includes sequencing all or a subset of the barcoded transcript-specific nucleic acids in the library to identify transcript-specific nucleic acids.
[0029] In certain embodiments, the method further includes comparing the barcoded target nucleic acids to the transcript-specific nucleic acids in a single cell.
[0030] In certain embodiments, the generation of a library comprising the barcoded target nucleic acids comprises (i) amplifying the barcoded target nucleic acids by contacting the pool of barcoded nucleic acids with one or more primers coupled to a label to generate amplified barcoded target nucleic acids coupled to the label, wherein the one or more primers specifically hybridize to the barcoded target nucleic acids and (ii) isolating the amplified target nucleic acids coupled to the label to generate the library. In certain embodiments, the label comprises biotin. In certain embodiments, isolating the amplified target nucleic acids coupled to the label comprises contacting the sample with an agent that binds to the label. In certain embodiments, the agent comprises streptavidin.
[0031] In certain embodiments, the mutation-specific probes are padlock probes. In certain embodiments, the padlock probes comprise a first homology region that is complementary to a first sequence of the target nucleic acid and a second homology region that is complementary to a second sequence of the target nucleic acid, and wherein the gap of at least one nucleotide is located between the first homology region and the second homology region (e.g., when hybridized to the target nucleic acid). In certain embodiments, the padlock probe generates a gap of at least one nucleotide upon hybridization to the target nucleic acid.
[0032] In certain embodiments, the mutation-specific probes comprise a pair of linear probes. In certain embodiments, one probe of the pair of linear probes comprises a first homology region that is complementary to a first sequence of the target nucleic acid and the second probe of the pair of linear probes comprises a second homology region that is complementary to a second sequence of the target nucleic acid, and wherein the gap of at least one nucleotide is located between the first homology region and the second homology region (e.g., when hybridized to the target nucleic acid). In certain embodiments, the pair of linear probes generates a gap of at least one nucleotide upon hybridization to the target nucleic acid.
[0033] In certain embodiments, the gap of at least one nucleotide corresponds to at least one nucleotide that is variant in the target nucleic acid compared to a reference sequence.
[0034] In certain embodiments, the gap of at least one nucleotide corresponds to the nucleotides that are variant in the target nucleic acid.
[0035] 516578835.1 6Attorney Ref. No. 00B206.1727
[0036] In certain embodiments, the mutation-specific probes and / or the transcriptome-specific probes comprise one or more of the following: (a) constant region sequence, (b) a spacer sequence and (c) a capture sequence. In certain embodiments, the constant region sequence, the spacer sequence or the capture sequence comprises a primer binding nucleotide sequence for use in amplifying the barcoded target nucleic acids.
[0037] In certain embodiments, the polynucleotides comprising the barcode further comprises a sequence that hybridizes to the capture sequence of the mutation-specific probes and / or the transcriptome-specific probes.
[0038] In certain embodiments, the plurality of cells or nuclei are treated with a fixative prior to step (a).
[0039] In certain embodiments, the plurality of cells is permeabilized or lysed prior to step (a). In certain embodiments, the compartments are emulsion droplets. In certain embodiments, the emulsion droplets are generated in an emulsion droplet generating device or generated using an emulsion droplet generating technique.
[0040] In certain embodiments, the target nucleic acid comprises RNA.
[0041] In certain embodiments, the target nucleic acid comprises DNA.
[0042] In certain embodiments, the plurality of cells comprises cancer cells.
[0043] In certain embodiments, the methods of the present disclosure are for use in identifying a variant of a target nucleic acid in a sample from a subject.
[0044] In certain embodiments, the methods of the present disclosure are for use diagnosing a disease in a subject.
[0045] In certain embodiments, the methods of the present disclosure are for use diagnosing a cancer in a subject.
[0046] The present disclosure further provides mutation-specific probes (and compositions thereof) for use in the methods disclosed herein. In certain embodiments, the mutation-specific probe comprises (a) a left homology site comprising a sequence that is complementary to a first sequence of a target nucleic acid, (b) a spacer sequence, (c) a capture sequence, (d) a probe barcode sequence, (e) a constant region and (f) a right homology site comprising a sequence that is complementary to a sequence of the target nucleic acid. In certain embodiments, the mutation-specific probe comprises a gap of at least one nucleotide and / or generates a gap of at least one nucleotide upon hybridization of the left homology site and the right homology site to the target nucleic acid. In certain embodiments, the gap corresponds to or includes the variant sequence in the target nucleic acid. In certain embodiments, the spacer sequence comprises a nucleotide sequence that has about 75%, about 80%, about 85%, about 90%, about
[0047] 516578835.1 7Attorney Ref. No. 00B206.1727
[0048] 95%, about 96%, about 97%, about 98%, about 99% or about 100% homology to SEQ ID NO: 1. In certain embodiments, the capture sequence comprises a nucleotide sequence that has about 75%, about 80%, about 85%, about 90%, about 95%, about 96%, about 97%, about 98%, about 99% or about 100% homology to SEQ ID NO: 3. In certain embodiments, the constant region comprises a nucleotide sequence that has about 75%, about 80%, about 85%, about 90%, about 95%, about 96%, about 97%, about 98%, about 99% or about 100% homology to SEQ ID NO: 2.
[0049] The present disclosure further provides kits for performing a method of the present disclosure. In certain embodiments, a kit of the present disclosure comprises a mutationspecific probe disclosed herein.
[0050] The present disclosure further provides systems for performing a method of the present disclosure. In certain embodiments, a system of the present disclosure comprises a mutationspecific probe disclosed herein.
[0051] BRIEF DESCRIPTION OF THE FIGURES
[0052] The following figures are included to illustrate certain aspects of the present disclosure and should not be viewed as exclusive embodiments. The subject matter disclosed is capable of considerable modifications, alterations, combinations and equivalents in form and function, without departing from the scope of this disclosure.
[0053] FIG. 1 provides a schematic of an exemplary method of the present disclosure.
[0054] FIG. 2 provides a schematic of an exemplary gap filling process of the present disclosure.
[0055] FIG. 3A provides exemplary schematics of a padlock probe for hybridizing to a target nucleic acid, a pre-amplification mutation-specific nucleic acid, a sample index amplicon and a library construct of the present disclosure.
[0056] FIG. 3B provides exemplary schematics of a pair of linear probes for hybridizing to a target nucleic acid, a pre-amplification mutation-specific nucleic acid, a sample index amplicon and a library construct of the present disclosure.
[0057] FIG. 4 provides the results of an exemplary nucleic acid detection method that uses direct ligation at 25°C or 40°C.
[0058] FIG. 5 provides the results of an exemplary method of the present disclosure that includes the use of a gap filling process.
[0059] 516578835.1 8Attorney Ref. No. 00B206.1727
[0060] FIG. 6 provides the results of an exemplary nucleic acid detection method that uses either linear or padlock probes for detecting the mutation DNAJB1 C.558OA and direct ligation.
[0061] FIG. 7 provides the mapping rate and signal to noise ratio for an exemplary method of the present disclosure.
[0062] FIG. 8 provides the mapping rate and signal to noise ratio for exemplary methods of the present disclosure that include decrosslinking.
[0063] FIG. 9 provides the allele dropout rate for an exemplary method of the present disclosure.
[0064] DETAILED DESCRIPTION
[0065] The present disclosure relates to methods for detecting variant nucleic acids present in single cells. In certain embodiments, methods of the present disclosure can be used to generate libraries of the variant nucleic acids. In certain embodiments, the present disclosure further provides methods for sequencing the libraries generated from the variant nucleic acids. In certain embodiments, methods of the present disclosure comprise a gap filling process that includes the use of reversible terminator nucleotides and ligation to improve accuracy in the detection of variant nucleic acids and reduce the detection of false positives.
[0066] For clarity, but not by way of limitation, the detailed description of the presently disclosed subject matter is divided into the following subsections:
[0067] I. Definitions;
[0068] II. Variant Nucleic Acids;
[0069] III. Cells;
[0070] IV. Methods of Detecting Variant Nucleic Acids; and
[0071] V. Kits;
[0072] VI. Systems; and
[0073] VII. Exemplary Embodiments.
[0074] I. DEFINITIONS
[0075] Unless defined otherwise, all technical and scientific terms used herein have the meaning commonly understood by a person skilled in the art to which the subject matter of the present disclosure belongs. The following references provide one of skill with a general definition of many of the terms used in the present disclosure: Singleton et al., Dictionary of Microbiology and Molecular Biology (2nd ed. 1994); The Cambridge Dictionary of Science
[0076] 516578835.1 9Attorney Ref. No. 00B206.1727
[0077] and Technology (Walker ed., 1988); The Glossary of Genetics, 5th Ed., R. Rieger et al. (eds.), Springer Verlag (1991); and Hale & Marham, The Harper Collins Dictionary of Biology (1991). As used herein, the following terms have the meanings ascribed to them below, unless specified otherwise.
[0078] As used herein, the use of the word “a” or “an” when used in conjunction with the term “comprising” in the claims and / or the specification can mean “one,” but it is also consistent with the meaning of “one or more,” “at least one,” and “one or more than one.”
[0079] The term “about” or “approximately” means within an acceptable error range for the particular value as determined by one of ordinary skill in the art, which depends in part on how the value is measured or determined, / .<?., the limitations of the measurement system. For example, “about” can mean within 3 or more than 3 standard deviations, per the practice in the art. Alternatively, “about” can mean a range of up to 20%, preferably up to 10%, more preferably up to 5%, and more preferably still up to 1% of a given value. Alternatively, particularly with respect to biological systems or processes, the term can mean within an order of magnitude, preferably within 5-fold, and more preferably within 2-fold, of a value.
[0080] The term “amplification process” refers generally to any process where a portion of a nucleic acid is copied or replicated into at least one additional nucleic acid molecule.
[0081] The term “antibody” herein is used in the broadest sense and encompasses various antibody structures, including but not limited to monoclonal antibodies, polyclonal antibodies, multispecific antibodies (e.g., bispecific antibodies) and antibody fragments so long as they exhibit the desired antigen-binding activity.
[0082] An “antibody fragment” refers to a molecule other than an intact antibody that comprises a portion of an intact antibody that binds the antigen to which the intact antibody binds. Examples of antibody fragments comprise but are not limited to Fv, Fab, Fab’, Fab’-SH, F(ab’)2, diabodies, linear antibodies, single-chain antibody molecules (e.g., scFv) and multispecific antibodies formed from antibody fragments.
[0083] As used herein, the term “compartment” refers to an area or volume that separates or isolates one or more components from other components. Non-limiting examples of compartments include vials, tubes, wells, droplets, boluses, vessels or areas or volumes separated by physical forces such as fluid flow, magnetism, electrical current or the like.
[0084] The terms “comprise(s),” “comprise(s),” “having,” “has,” “can,” “contain(s)” and variants thereof, as used herein, are intended to be open-ended transitional phrases, terms or words that do not preclude additional acts or structures. The present disclosure also
[0085] 516578835.1 10Attorney Ref. No. 00B206.1727
[0086] contemplates other embodiments “comprising,” “consisting of’ and “consisting essentially of,” the embodiments or elements presented herein, whether explicitly set forth or not.
[0087] The term “coupled” can refer to the connecting or uniting of two or more components by an interaction, bond, link, force or tie in order to keep two or more components together. In certain embodiments, the term “coupled” encompasses either direct or indirect binding where, for example, a first component is directly bound to a second component, or one or more intermediate molecules are disposed between the first component and the second component. Exemplary bonds comprise covalent bonds, ionic bonds, van der Waals interactions and other bonds identifiable by a skilled person.
[0088] The terms “detect” or “detection,” as used herein, indicate the determination of the existence and / or presence of a target, e.g., a nucleic acid target (e.g., a variant target nucleic acid), in a limited portion of space, including but not limited to a sample. The terms “detect” or “detection,” as used herein, can comprise determination of chemical and / or biological properties of the target, including but not limited to ability to interact, and in particular bind, other compounds, ability to activate another compound and additional properties identifiable by a skilled person upon reading of the present disclosure. The detection can be quantitative or qualitative. A detection is “quantitative” when it refers, relates to, or involves the measurement of quantity or amount of the target or signal (also referred as quantitation), which comprises but is not limited to any analysis designed to determine the amounts or proportions of the target or signal. A detection is “qualitative” when it refers, relates to, or involves identification of a quality or kind of the target or signal in terms of relative abundance to another target or signal, which is not quantified.
[0089] As used herein, the term “emulsion droplet” refers to droplets formed by at least two immiscible phases, e.g., a continuous phase and a dispersed phase. In certain embodiments, the emulsion droplets can be formed in an emulsion droplet generating device using the addition of oil as the continuous phase into the emulsion droplet generating device. In certain embodiments, the emulsion droplets can be formed by a technique that produces emulsion droplets such as, but not limited to, vortexing.
[0090] The terms “expression” or “expresses,” as used herein, refer to transcription and translation occurring within a cell. The level of expression of a gene and / or nucleic acid in a cell can be determined on the basis of either the amount of corresponding mRNA that is present in the cell or the amount of the protein encoded by the gene and / or nucleic acid that is produced by the cell. For example, mRNA transcribed from a gene and / or nucleic acid is desirably quantitated by northern hybridization. Sambrook et al., Molecular Cloning: A Laboratory
[0091] 516578835.1 11Attorney Ref. No. 00B206.1727
[0092] Manual, pp. 7.3-7.57 (Cold Spring Harbor Laboratory Press, 1989). Protein encoded by a gene and / or nucleic acid can be quantitated either by assaying for the biological activity of the protein or by employing assays that are independent of such activity, such as western blotting or radioimmunoassay using antibodies that are capable of reacting with the protein. Sambrook et al., Molecular Cloning: A Laboratory Manual, pp. 18.1-18.88 (Cold Spring Harbor Laboratory Press, 1989).
[0093] As used herein, the term “hybridization,” refers to the process in which two singlestranded polynucleotides bind non-covalently to form a stable double-stranded polynucleotide.
[0094] As used herein, the term “individual” or “subject” refers to a vertebrate or an invertebrate, such as a human or non-human animal, for example, a mammal. Mammals comprise, but are not limited to, humans, non-human primates, farm animals, sport animals, rodents and pets. Non-limiting examples of non-human animal subjects comprise rodents such as mice, rats, hamsters, guinea pigs, rabbits, dogs, cats, sheep, pigs, goats, cattle, horses, apes and monkeys. In certain embodiments, the individual or subject is a human.
[0095] As used herein, the term “zw vitro" refers to an artificial environment and to processes or reactions that occur within an artificial environment. In vitro environments exemplified, but are not limited to, test tubes and cell cultures.
[0096] An “isolated nucleic acid” refers to a nucleic acid molecule that has been separated from a component of its environment, e.g., natural environment. An isolated nucleic acid includes a nucleic acid molecule contained in cells that ordinarily contain the nucleic acid molecule, but the nucleic acid molecule is present extrachromosomally or at a chromosomal location that is different from its natural chromosomal location.
[0097] As used herein, a “label” or “marker” refers to an agent that allows for direct or indirect detection or for isolation (e.g., of a nucleic acid). Labels comprise, but are not limited to, fluorescent labels, chromogenic labels, electron dense labels, chemiluminescent labels and radioactive labels. Non-limiting examples of labels comprise green fluorescent protein (“GFP”), mCherry, dtTomato, or other fluorescent proteins known in the art (e.g., Shaner et al., A Guide to Choosing Fluorescent Proteins, Nature Methods 2(12):905-909 (2005) incorporated by reference herein,32P,14C,125I,3H and131I, fluorogens (such as Rare Earth Chelate or lucifer yellow and its derivatives), Rhodamine (rhodamine) and its derivatives, dansyl, umbelliferone, luciferase (such as firefly luciferase and bacterial fluorescence plain enzyme) (U.S. Patent number 4,737,456), fluorescein, 2,3-dihydros phthalazine diketone, as well as enzymes producing detectable signals, e.g., horseradish peroxidase (HRP), alkaline phosphorus sour enzyme, beta galactosidase, glucoamylase, lysozyme, carbohydrate oxidase
[0098] 516578835.1 12Attorney Ref. No. 00B206.1727
[0099] (such as glucose oxidase, galactose oxidase and glucose-6-phosphate dehydrogenase (G6PD)) and heterocyclic oxidases (such as uricase and xanthine oxidase). In certain embodiments, a label can be used for the isolation of a molecule, e.g., a nucleic acid.
[0100] The term “ligation,” as used herein, refers to the formation of a covalent bond or linkage between two or more molecules, e.g., between the termini of two or more nucleic acid molecules. As used herein, the term “ligation process” refers generally to a process for covalently linking two or more molecules together by an enzyme. For example, two or more nucleic acid molecules can be covalently linked together by a ligation process using a ligase.
[0101] The term “monoclonal antibody,” as used herein, refers to an antibody obtained from a population of substantially homogeneous antibodies, / .<?., the individual antibodies comprising the population are identical and / or bind the same epitope, except for possible variant antibodies, e.g., containing naturally occurring mutations or arising during production of a monoclonal antibody preparation, such variants generally being present in minor amounts. In contrast to polyclonal antibody preparations, which typically comprise different antibodies directed against different determinants (epitopes), each monoclonal antibody of a monoclonal antibody preparation is directed against a single determinant on an antigen. Thus, the modifier “monoclonal” indicates the character of the antibody as being obtained from a substantially homogeneous population of antibodies, and is not to be construed as requiring production of the antibody by any particular method. For example, the monoclonal antibodies to be used in accordance with the presently disclosed subject matter may be made by a variety of techniques, including but not limited to the hybridoma method, recombinant DNA methods, phage-display methods, and methods utilizing transgenic animals containing all or part of the human immunoglobulin loci, such methods and other exemplary methods for making monoclonal antibodies being described herein.
[0102] The term “nucleic acid” or “polynucleotide” comprises any compound and / or substance that comprises a polymer of nucleotides. Each nucleotide is composed of a base, specifically a purine- or pyrimidine base ( / .<?., cytosine (C), guanine (G), adenine (A), thymine (T) or uracil (U)), a sugar ( / .<?., deoxyribose or ribose), and a phosphate group. Often, the nucleic acid molecule is described by the sequence of bases, whereby said bases represent the primary structure (linear structure) of a nucleic acid molecule. The sequence of bases is typically represented from 5’ to 3’. The term nucleic acid encompasses deoxyribonucleic acid (DNA) including, e.g., complementary DNA (cDNA) and genomic DNA, ribonucleic acid (RNA), e.g., messenger RNA (mRNA), synthetic forms of DNA or RNA, and mixed polymers comprising two or more of these molecules. The nucleic acid molecule can be linear or circular.
[0103] 516578835.1 13Attorney Ref. No. 00B206.1727
[0104] In addition, the term nucleic acid comprises both, sense and antisense strands, as well as single stranded and double stranded forms. Moreover, the herein described nucleic acid can contain naturally occurring or non-naturally occurring nucleotides. Examples of non-naturally occurring nucleotides comprise modified nucleotide bases with derivatized sugars or phosphate backbone linkages or chemically modified residues.
[0105] The term “oligonucleotide,” as used herein, refers to a short nucleic acid sequence comprising from about 2 to about 100 nucleotides (e.g., about 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 99 or 100 nucleotides, or a range defined by any of the foregoing values). The terms “nucleic acid” and “polynucleotide” as used herein refer to a polymeric form of nucleotides of any length, either ribonucleotides (RNA) or deoxyribonucleotides (DNA). These terms refer to the primary structure of the molecule, and thus include double- and single-stranded DNA, and double- and single-stranded RNA. The terms include, as equivalents, analogs of either RNA or DNA made from nucleotide analogs and modified polynucleotides such as, for example, methylated and / or capped polynucleotides. Nucleic acids are typically linked via phosphate bonds to form nucleic acid sequences or polynucleotides, though many other linkages are known in the art (e.g., phosphorothioates, boranophosphates, and the like).
[0106] Any of the oligonucleotides described herein can be modified in any suitable manner so as to stabilize or enhance the binding affinity of the oligonucleotide for its target. For example, an oligonucleotide sequence as described herein can comprise one or more modified oligonucleotide bases.
[0107] Any of the oligonucleotide sequences described herein can comprise, consist essentially of, or consist of a complement of any of the sequences disclosed herein. The terms “complement” or “complementary sequence,” as used herein, refer to a nucleic acid sequence that forms a stable duplex with an oligonucleotide described herein via Watson-Crick base pairing rules, and typically shares about 80%, about 81%, about 82%, about 83%, about 84%, about 85%, about 86%, about 87%, about 88%, about 89%, about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, or about 99% greater identity with the disclosed oligonucleotide.
[0108] The oligonucleotides described herein can be prepared using any suitable method, a variety of which are known in the art (see, for example, Sambrook et al., Molecular Cloning. A Laboratory Manual, 1989, 2. Supp. Ed., Cold Spring Harbour Laboratory Press: New York, N.Y.; M. A. Innis (Ed.), PCR Protocols. A Guide to Methods and Applications, Academic Press: New York, N.Y. (1990); P. Tijssen, Hybridization with Nucleic Acid Probes -
[0109] 516578835.1 14Attorney Ref. No. 00B206.1727
[0110] Laboratory Techniques in Biochemistry and Molecular Biology (Parts I and II), Elsevier Science (1993); M. A. Innis (Ed.), PCR Strategies, Academic Press: New York, N.Y. (1995); and F. M. Ausubel (Ed.), Short Protocols in Molecular Biology, John Wiley & Sons: Secaucus, N.J. (2002); Narang et al., Meth. Enzymol., 68: 90-98 (1979); Brown et al., Meth. Enzymol., 68: 109-151 (1979); and Belousov et al., Nucleic Acids Res., 25: 3440-3444 (1997), each of which is incorporated herein by reference in its entirety). Oligonucleotide pairs also can be designed using a variety of tools, such as the Primer-BLAST tool provided by the National Center of Biotechnology Information (NCBI). Oligonucleotide synthesis can be performed on oligo synthesizers such as those commercially available from Perkin Elmer / Applied Biosystems, Inc. (Foster City, CA), DuPont (Wilmington, DE), or Milligen (Bedford, MA). Alternatively, oligonucleotides can be custom made and obtained from a variety of commercial sources well-known in the art, including, for example, the Midland Certified Reagent Company (Midland, TX), Eurofins Scientific (Louisville, KY), BioSearch Technologies, Inc. (Novato, CA), and the like. Oligonucleotides can be purified using any suitable method known in the art, such as, for example, native acrylamide gel electrophoresis, anion-exchange HPLC (see, e.g., Pearson et al., J. Chrom., 255: 137-149 (1983), incorporated herein by reference), and reverse phase HPLC (see, e.g., McFarland et al., Nucleic Acids Res., 7: 1067-1080 (1979), incorporated herein by reference).
[0111] The sequence of the oligonucleotides can be verified using any suitable sequencing method known in the art, including, but not limited to, chemical degradation (see, e.g., Maxam et al., Methods of Enzymology, 65: 499-560 (1980), incorporated herein by reference), matrix-assisted laser desorption ionization time-of-flight (MALDI-TOF) mass spectrometry (see, e.g., Pieles et al., Nucleic Acids Res., 21: 3191-3196 (1993), incorporated herein by reference), mass spectrometry following a combination of alkaline phosphatase and exonuclease digestions (Wu et al., Anal. Biochem., 29).
[0112] As used herein, the term “partitioning” refers generally to the separation of one or more components from other components in an area or volume.
[0113] As used herein, “percentage of sequence identity” or “percentage of identity” means the value determined by comparing two optimally aligned sequences over a comparison window, wherein the portion of the polynucleotide sequence in the comparison window can comprise additions or deletions (gaps) as compared to the reference sequence (which does not comprise additions or deletions) for optimal alignment of the two sequences. The percentage is calculated by determining the number of positions at which the identical nucleic acid base or amino acid residue occurs in both sequences to yield the number of matched positions,
[0114] 516578835.1 15Attorney Ref. No. 00B206.1727
[0115] dividing the number of matched positions by the total number of positions in the window of comparison, and multiplying the result by 100 to yield the percentage of sequence identity. As understood by those skilled in the art, determination of percent identity between any two sequences can be accomplished using certain well-known mathematical algorithms. Nonlimiting examples of such mathematical algorithms are the algorithm of Myers and Miller, the local homology algorithm of Smith et al.; the homology alignment algorithm of Needleman and Wunsch; the search-for-similarity-method of Pearson and Lipman; the algorithm of Karlin and Altschul, modified as in Karlin and Altschul. Computer implementations of suitable mathematical algorithms can be utilized for comparison of sequences to determine sequence identity. Such implementations comprise, but are not limited to: CLUSTAL, ALIGN, GAP, BESTFIT, BLAST, FASTA, among others identifiable by skilled persons. Sequence alignment algorithms also are disclosed in, for example, Altschul et al., J. Molecular Biol., 215(3): 403-410 (1990); Beigert et al., Proc. Natl. Acad. Sci. USA, 106(10): 3770-3775 (2009), Durbin et al., eds., Biological Sequence Analysis: Probalistic Models of Proteins and Nucleic Acids, Cambridge University Press, Cambridge, UK (2009); Soding, Bioinformatics, 21(7): 951-960 (2005); Altschul et al., Nucleic Acids Res., 25(17): 3389-3402 (1997); and Gusfield, Algorithms on Strings, Trees and Sequences, Cambridge University Press, Cambridge UK (1997), each of which is incorporated herein by reference in its entirety).
[0116] The term “plurality” refers to a number larger than one. In certain embodiments, the term “plurality of cells” refers to a number of cells larger than one. For example, but not by way of limitation, a plurality of cells includes at least two cells. In certain embodiments, a plurality of cells includes about 10,000 or more cells, about 20,000 or more cells, about 30,000 or more cells, about 40,000 or more cells, about 50,000 or more cells, about 100,000 or more cells, about 150,000 or more cells, about 200,000 or more cells, about 300,000 or more cells, about 400,000 or more cells or 500,000 or more cells. In certain embodiments, the term “plurality of nucleic acids” refers to a number of nucleic acids larger than one. For example, but not by way of limitation, a plurality of nucleic acids comprises at least two nucleic acids. In certain embodiments, the term “plurality of particles” refers to a number of particles larger than one. For example, but not by way of limitation, a plurality of particles comprises at least two particles.
[0117] The terms “primer,” “primer sequence,” “primer oligonucleotide,” and “amplification oligonucleotide” as used herein, refer to an oligonucleotide which is capable of acting as a point of initiation of synthesis of an extension product that is a complementary strand of nucleic acid (all types of DNA or RNA) when placed under suitable amplification conditions (e.g.,
[0118] 516578835.1 16Attorney Ref. No. 00B206.1727
[0119] buffer, salt, temperature and pH) in the presence of nucleotides and an agent for nucleic acid polymerization (e.g., a DNA-dependent or RNA-dependent polymerase). The amplification oligonucleotides of the present disclosure can be of any suitable size, and desirably comprise, consist essentially of, or consist of about 15 to 50 nucleotides, preferably about 20 to 40 nucleotides. The oligonucleotides of the present disclosure can contain additional nucleotides in addition to those described herein.
[0120] As used herein, “reference sequence” is a defined sequence used as a basis for sequence comparison. A reference sequence can be a subset or the entirety of a specified sequence; for example, as a segment of a full-length protein or protein fragment or a gene sequence or fragment of a gene sequence. A reference sequence can be, for example, a sequence identifiable in a database such as GenBank and UniProt and others identifiable to those skilled in the art. In certain embodiments, a reference sequence can be a “wild type” sequence for a sequence of interest. In certain embodiments, a nucleic acid that contains a sequence that varies from a reference sequence can be referred to as a “mutant,” “variant” or “variant nucleic acid.” The term “reverse-transcription process” refers to a process of generating a complementary strand of DNA using an enzyme called a reverse transcriptase.
[0121] The term “sample,” as used herein, refers to any sample containing one or more individual cells. In certain embodiments, “sample” refers to a sample of biological material obtained from a subject, e.g., a tissue biopsy or a tissue sample. In certain embodiments, the sample can be obtained from a tissue, e.g, a tissue sample. Non-limiting examples of tissues comprise eye, muscle, skin, tendon, vein, artery, blood, heart, spleen, lymph node, bone, bone marrow, lung, bronchi, trachea, gut, small intestine, large intestine, colon, rectum, salivary gland, tongue, gallbladder, appendix, liver, pancreas, brain, stomach, skin, kidney, ureter, bladder, urethra, gonad, testicle, ovary, uterus, fallopian tube, thymus, pituitary, thyroid, adrenal or parathyroid tissue. In certain embodiments, the samples are obtained from a subject. In certain embodiments, the subject can be a human, non-human primate, e.g, an ape or a monkey, a farm animal, a mouse, a rat, a hamster, a guinea pig, a rabbit, a dog, cat, a sheep, a pig, a goat, a cow or a horse. In certain embodiments, the subject is a human. In certain embodiments, the sample can be obtained from preserved tissue, e.g., fixed tissue, from frozen tissue or from fresh tissue, e.g., tissue samples. In certain embodiments, a sample that can be analyzed using the methods of the present disclosure comprises at least two or more cells. For example, but not by way of limitation, a sample can comprise about 10 or more cells and / or nuclei, about 100 or more cells and / or nuclei, about 1,000 or more cells and / or nuclei, about 5,000 or more cells and / or nuclei, about 10,000 or more cells and / or nuclei, about 20,000 or
[0122] 516578835.1 17Attorney Ref. No. 00B206.1727
[0123] more cells and / or nuclei, about 30,000 or more cells and / or nuclei, about 40,000 or more cells and / or nuclei, about 50,000 or more cells and / or nuclei, about 100,000 or more cells and / or nuclei, about 150,000 or more cells and / or nuclei, about 200,000 or more cells and / or nuclei, about 300,000 or more cells and / or nuclei, about 400,000 or more cells and / or nuclei, about 500,000 or more cells and / or nuclei, about 1,000,000 or more cells and / or nuclei, about 2,000,000 or more cells and / or nuclei, about 3,000,000 or more cells and / or nuclei, about 4,000,000 or more cells and / or nuclei or about 5,000,000 or more cells and / or nuclei. In certain embodiments, the cells and / or nuclei of a sample are obtained from (e.g., isolated from) a tissue.
[0124] As used herein, “sequence identity” or “identity” in the context of two nucleic acid or polypeptide sequences makes reference to the nucleotide bases or amino acid residues in the two sequences that are the same when aligned for maximum correspondence over a specified comparison window. When percentage of sequence identity or similarity is used in reference to proteins, it is recognized that residue positions which are not identical often differ by conservative amino acid substitutions, where amino acid residues are substituted with a functionally equivalent residue of the amino acid residues with similar physiochemical properties and therefore do not change the functional properties of the molecule.
[0125] As used herein, the terms “set,” “primer set,” “probe set,” and “primer and probe set,” refer to two or more oligonucleotides which together are capable of priming the amplification of a target sequence or target nucleic acid of interest (e.g. , a target sequence within an infectious agent) and / or at least one probe which can detect the target sequence or target nucleic acid. In certain embodiments, the term “set” refers to a pair of oligonucleotides including a first oligonucleotide, referred herein as a “forward primer” that hybridizes with the 5 ’-end of the target sequence or target nucleic acid to be amplified and a second oligonucleotide, referred herein as a “reverse primer” that hybridizes with the complement of the target sequence or target nucleic acid to be amplified.
[0126] The term “specifically binds,” as used herein, refers to the preferential binding to a target molecule, e.g, a protein or nucleic acid, relative to other molecules, e.g, proteins or nucleic acids, in a sample.
[0127] As used herein, the term “subset” refers to a small portion of a larger quantity of material.
[0128] As used herein, “treatment” (and grammatical variations thereof such as “treat” or “treating”) refers to clinical intervention in an attempt to alter the natural course of a disease in the individual being treated, and can be performed either for prophylaxis or during the course of clinical pathology. Desirable effects of treatment comprise, but are not limited to, preventing
[0129] 516578835.1 18Attorney Ref. No. 00B206.1727
[0130] occurrence or recurrence of disease, alleviation of symptoms, diminishment of any direct or indirect pathological consequences of the disease, preventing metastasis, decreasing the rate of disease progression, amelioration or palliation of the disease state, and remission or improved prognosis. The decrease can be at least a 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95%, 98% or 99% decrease in severity of complications, signs or symptoms or in likelihood of progression to another grade. “Treatment” can also refer to inhibiting proliferation of a cancer or progression to a higher grade by at least 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95%, 98% or 99%. In certain embodiments, gRNAs identified by methods of the present disclosure can used to delay development of a disease or to slow the progression of a disease.
[0131] A “variant” or “nucleic acid variant,” as used herein, refers to a nucleic acid that comprise modifications, e.g., variations, compared to a wild type nucleic acid (e.g., a reference sequence). Non-limiting modifications include nucleotide substitutions (e.g., single nucleotide substitutions), translocations, mutations, deletions and insertions. In certain embodiments, a wild type nucleic acid is the most common form of the nucleic acid occurring in nature. In certain embodiments, the nucleic acid variant is a minority variant. In certain embodiments, a minority variant is a low-frequency variant. In certain embodiments, a nucleic acid variant can differ from the wild type nucleic acid by at least one nucleotide modification, e.g., from about one to about ten nucleotide modifications. In certain embodiments, the sequence of a nucleic acid variant has at least about 80%, at least about 90%, at least about 95% or at least about at least about 99% identity to a wild type nucleic acid sequence. In certain embodiments, a nucleic acid variant can differ from a different variant of the nucleic acid by at least one nucleotide modification, e.g., from about one to about ten nucleotide modifications. In certain embodiments, a “genetic variant” or “genomic variant” can refer to a substitution, inversion, insertion or deletion of one or more nucleotides at a genetic locus, or a translocation of DNA from one genetic locus to another genetic locus. In certain embodiments, “genetic variant” means an alternative nucleotide sequence at a genetic locus that can be present in a population of individuals and that includes nucleotide substitutions, insertions, and deletions with respect to other members of the population (e.g., polymorphisms, mutations, etc.).
[0132] II. VARIANT NUCLEIC ACIDS
[0133] The present disclosure provides methods for detecting a variant of a target nucleic acid in a sample, e.g., in a plurality of cells and / or nuclei. For example, but not by way of limitation, the present disclosure provides methods for detecting variants of a genomic sequence (e.g.,
[0134] 516578835.1 19Attorney Ref. No. 00B206.1727
[0135] genomic variants) in a sample. In certain embodiments, methods of the present disclosure can be used to identify nonsense, missense, frameshift and / or silent mutations present in genomic sequences.
[0136] In certain embodiments, methods of the present disclosure can be used to detect variants in a locus of interest in a nucleic acid sample. In certain embodiments, methods of the present disclosure can be used to detect a nucleic acid variant that is a minority variant. In certain embodiments, a minority variant is a low-frequency variant. For example, but not by way of limitation, methods of the present disclosure can be used to detect variants that occur at a frequency of about 5% or less in the population being assayed, including at about 3% or less, about 1% or less and even at a frequency of about 0.5% or less of the population being analyzed. In certain embodiments, a nucleic acid variant can differ from the wild type nucleic acid (e.g., a reference sequence) by at least one nucleotide modification, e.g., from about one to about ten nucleotide modifications. In certain embodiments, the sequence of a nucleic acid variant has at least about 80%, at least about 90%, at least about 95%, at least about 99% identity, at least about 99.1% identity, at least about 99.2% identity, at least about 99.3% identity, at least about 99.4% identity, at least about 99.5% identity, at least about 99.6% identity, at least about 99.7% identity, at least about 99.8% identity or at least about 99.9% identity to a wild type nucleic acid sequence. In certain embodiments, a nucleic acid variant can differ from a different variant of the nucleic acid by at least one nucleotide modification, e.g, from about one to about ten nucleotide modifications. For example, but not by way of limitation, methods of the present disclosure can be used to detect single nucleotide polymorphisms (SNPs). In certain embodiments, methods of the present disclosure can be used to detect single nucleotide variant (SNVs).
[0137] In certain embodiments, methods of the present disclosure can be used to identify nucleic acid variants, e.g, genomic variants, that result in a higher risk and / or cause a disorder in a subject. For example, but not by way of limitation, methods of the present disclosure can be used to identify nucleic acid variants, e.g., genomic variants, that result in a higher risk or cause cancer, e.g., bladder cancer, bone cancer, brain cancer, breast cancer, cervical cancer, colorectal cancer, head and neck cancer, kidney cancer, leukemia, lung cancer, lymphoma, melanoma, pancreatic cancer, parathyroid cancer, prostate cancer, skin cancer, stomach cancer, testicular cancer, thyroid cancer and uterine cancer, in a subject. In certain embodiments, methods of the present disclosure can be used to identify nucleic acid variants, e.g., genomic variants, that result in a higher risk or causes developmental delays, skeletal disorders, ectodermal dysplasia, cleft lip and / or cleft palate, and malformations of the hands and feet.
[0138] 516578835.1 20Attorney Ref. No. 00B206.1727
[0139] Non-limiting examples of variant nucleic acids are provided in Table 1. In certain embodiments, methods of the present disclosure can be used to determine treatment methods for subjects that have a genetic mutation, e.g., that increases the subject’s risk of having a disorder or causes a disorder. In certain embodiments, methods of the present disclosure can be used to identify nucleic acid variants that result in developmental changes and / or affect development. In certain embodiments, methods of the present disclosure can be used to identify nucleic acid variants that affect biological processes. In certain embodiments, methods of the present disclosure can be used for determining the spatial distributions of mutations of interest. In certain embodiments, methods of the present disclosure can be used for in situ identification of nucleic acid variants. In certain embodiments, the target nucleic acid is any nucleic acid, e.g., genomic nucleic acid sequence, that is known in the art as being mutated in a subject. In certain embodiments, the target nucleic acid is any nucleic acid, e.g., genomic nucleic acid sequence, that is known in the art as being mutated in a subject and results in a higher risk and / or causes a disorder in the subject. In certain embodiments, the variant of the target nucleic acid is any variant that is known in the art, e.g., any variant that has a known sequence.
[0140] In certain embodiments, the target nucleic acid is a tumor suppressor gene. In certain embodiments, the target nucleic acid is a variant of a tumor suppressor gene. Non-limiting examples of tumor suppressor genes include APC, BRCA1, BRCA2, DPC4, INKA, MADR2, NF1, NF2, p53, PTC, PTEN, Rb, VHL and QT1. For example, but not by way of limitation, the target nucleic acid is a variant of a tumor suppressor gene, e.g., APC, BRCA1, BRCA2, DPC4, INKA, MADR2, NF1, NF2, p53, PTC, PTEN, Rb, VHL and / or QT1.
[0141] In certain embodiments, the target nucleic acid is a DnaJ heat shock protein family (Hsp40) member Bl (DNAJB1) gene. In certain embodiments, the target nucleic acid is a variant of the DNAJB1 gene. In certain embodiments, a variant of the DNAJB1 gene is C.558OA (DNAJB1 c.558C>A)
[0142] In certain embodiments, the target nucleic acid is a Kirsten rat sarcoma viral oncogene homologue (KRAS) gene. In certain embodiments, the target nucleic acid is a variant of the KRAS gene. In certain embodiments, a variant of the KRAS gene is c.34G>T (KRAS c.34G>T).
[0143] In certain embodiments, the target nucleic acid is a fibroblast growth factor receptor 1 (FGFR1) gene. In certain embodiments, the target nucleic acid is a variant of the FGFR1 gene. In certain embodiments, a variant of the FGFR1 gene is c.719G>A (FGFR1 c.719G>A).
[0144] 516578835.1 21Attorney Ref. No. 00B206.1727
[0145] In certain embodiments, the target nucleic acid is a Protein Tyrosine Phosphatase Receptor C (PTPR) gene. In certain embodiments, the target nucleic acid is a variant of the PTPR gene. In certain embodiments, a variant of the PTPR gene is c.2306T>A (PTPRC c.2306T>A).
[0146] In certain embodiments, the target nucleic acid is a tumor protein p63 (TP63) gene. In certain embodiments, the target nucleic acid is a variant of the TP63 gene. In certain embodiments, a variant of the TP63 gene is c,1090G>A (TP63 c,1090G>A).
[0147] In certain embodiments, the target nucleic acid is a CTNNB1 gene. In certain embodiments, the target nucleic acid is a variant of the CTNNB1 gene.
[0148] In certain embodiments, the target nucleic acid is a CIC (Capicua) gene. In certain embodiments, the target nucleic acid is a variant of the Capicua gene.
[0149] In certain embodiments, the target nucleic acid is a tumor protein p53 (TP53) gene. In certain embodiments, the target nucleic acid is a variant of the TP53 gene.
[0150] In certain embodiments, the target nucleic acid is a phosphatase and tensin homolog (PTEN) gene. In certain embodiments, the target nucleic acid is a variant of the PTEN gene.
[0151] III. CELLS
[0152] The present disclosure provides a method for detecting variant target nucleic acids in different cell types. In certain embodiments, cells (e.g., the plurality of cells) that are to be analyzed by the methods of the present disclosure can be obtained from a subject. In certain embodiments, the subject can be a human, non-human primate, e.g., an ape or a monkey, a farm animal, a mouse, a rat, a hamster, a guinea pig, a rabbit, a dog, cat, a sheep, a pig, a goat, a cow or a horse. In certain embodiments, the subject is a human.
[0153] In certain embodiments, the cells (e.g., the plurality of cells) can be obtained from a biological fluid. Non-limiting examples of biological fluids comprise whole blood, plasma, serum, sweat, urine, sputum, spinal fluid, pleural fluid, mucus, nipple aspirates, lymph fluid, fluid of the respiratory, intestinal and genitourinary tracts, interstitial fluid, tear fluid, saliva, breast milk, fluid from the lymphatic system, semen, vaginal secretions, cerebrospinal fluid, intra-organ system fluid, ascitic fluid, tumor cyst fluid, amniotic fluid, bronchoalveolar fluid, biliary fluid and combinations thereof.
[0154] In certain embodiments, the cells (e.g., the plurality of cells) can be obtained from a tissue, e.g., a tissue sample, or are present in a tissue sample. In certain embodiments, the cells (e.g., the plurality of cells) can be obtained from a tissue, e.g., a tissue sample. In certain embodiments, the cells (e.g., the plurality of cells) are present in a tissue, e.g., in a tissue
[0155] 516578835.1 22Attorney Ref. No. 00B206.1727
[0156] sample. Non-limiting examples of tissues comprise eye, muscle, skin, tendon, vein, artery, blood, heart, spleen, lymph node, bone, bone marrow, lung, bronchi, trachea, gut, small intestine, large intestine, colon, rectum, salivary gland, tongue, gallbladder, appendix, liver, pancreas, brain, stomach, skin, kidney, ureter, bladder, urethra, gonad, testicle, ovary, uterus, fallopian tube, thymus, pituitary, thyroid, adrenal or parathyroid tissue.
[0157] In certain embodiments, the cells (e.g., the plurality of cells) can comprise primary cells, blood cells, somatic cells, epithelial cells, endothelial cells, fibroblast cells, microglia, neurons, astrocytes, cancer cells, cells derived from organoids or xenografts or stem cells, e.g., pluripotent stem cells (iPSCs) or embryonic stem cells. In certain embodiments, the cells can comprise primary cells. In certain embodiments, the cells for use in the present disclosure can be derived from stem cells, e.g, stem cells that have undergone natural differentiation or artificially induced reprogramming or transdifferentiation.
[0158] In certain embodiments, the cells (e.g., the plurality of cells) for use in the present disclosure can be fetal cells, e.g., obtained from or present in fetal tissue and / or amniotic fluid. In certain embodiments, the methods of the present disclosure can be used to analyze fetal health and / or identify an abnormality in individual fetal cells.
[0159] In certain embodiments, the cells (e.g., the plurality of cells) can be obtained from preserved samples, e.g., fixed samples, from frozen samples or from fresh samples, e.g., tissue samples. In certain embodiments, the cells (e.g., the plurality of cells) are present in preserved samples, e.g., fixed samples, frozen samples or fresh samples, e.g., tissue samples. For example, but not by way of limitation, the cells (e.g., the plurality of cells) can be obtained from a clinical sample, e.g., a tissue biopsy. In certain embodiments, the clinical sample can be a fixed clinical sample, e.g., a fixed tissue biopsy.
[0160] In certain embodiments, the cells (e.g., the plurality of cells) can be obtained from in vitro cell cultures. For example, but not by way of limitation, the cells (e.g., the plurality of cells) can comprise cell lines, e.g., H358 cells (non-small cell lung cancer (NSCLC) cell line), PC9 cells (NSCLC cell line) and / or K562 cells (chronic myeloid leukemia (CML) cell line).
[0161] In certain embodiments, the cells (e.g., the plurality of cells) can be immune cells. Nonlimiting examples of immune cells comprise neutrophils, eosinophils, basophils, mast cells, monocytes, macrophages, dendritic cells, natural killer cells (NK cells) and lymphocytes, e.g., B cells and T cells (e.g., cytotoxic T cells, natural killer T cells, regulatory T cells and helper T cells). In certain embodiments, the cells can be modified immune cells that have been genetically engineered to express a chimeric antigen receptor (CAR), e.g., CAR T cells and CAR NK cells.
[0162] 516578835.1 23Attorney Ref. No. 00B206.1727
[0163] In certain embodiments, the cells (e.g., the plurality of cells) can be obtained from and / or present in a malignancy of a tissue or a tumor. Non-limiting examples of such malignancies comprise carcinomas, adenocarcinomas, sarcomas and fibroadenomas. In certain embodiments, the cells are obtained from a cancer such as bladder cancer, bone cancer, brain cancer, breast cancer, cervical cancer, colorectal cancer, head and neck cancer, kidney cancer, leukemia, lung cancer, lymphoma, melanoma, pancreatic cancer, parathyroid cancer, prostate cancer, skin cancer, stomach cancer, testicular cancer, thyroid cancer and uterine cancer. In certain embodiments, the methods of the present disclosure can be used to identify mutations and / or gene alterations present in single cancer cells.
[0164] In certain embodiments, the cells can comprise diseased cells and healthy cells. For example, but not by way of limitation, the cells can comprise cells obtained from a tumor or cancer and comprise non-cancerous cells (e.g., healthy cells that were located adjacent to the tumor or cancer or healthy cells obtained from a subject that does not have cancer).
[0165] In certain embodiments, the cells (e.g., the plurality of cells) can comprise cells having different developmental stages. In certain embodiments, the cells can comprise cells of different disease states.
[0166] In certain embodiments, the cells (e.g., the plurality of cells) can be from any model organism. For example, but not by way of limitation, the model organism can be E. coli, yeast, Arabidopsis, xenopus, zebrafish, drosophila melanogaster, ascidians, nematodes, mice and monkeys.
[0167] In certain embodiments, the cells (e.g., the plurality of cells) can be cells that have been infected by an infectious agent. Non-limiting examples of infectious agents comprise viruses, bacteria, fungi and protozoans.
[0168] In certain embodiments, the cells (e.g., the plurality of cells) can be enriched for cells of interest to produce an enriched cell sample, which can be subjected to the methods of the present disclosure. Any technique known in the art can be used to enrich for the cells of interest. For example, but not by way of limitation, flow cytometry can be used to enrich for cells of interest to produce an enriched cell sample. In certain embodiments, FACS in combination with antibody labeling can be used to enrich for cells of interest to produce an enriched cell sample.
[0169] In certain embodiments, the cells (e.g., the plurality of cells) have been genetically modified to express and / or secrete an agent, e.g., a therapeutic agent. For example, but not by way of limitation, the cells to be used in the methods of the present disclosure to express an antibody or an antibody fragment.
[0170] 516578835.1 24Attorney Ref. No. 00B206.1727
[0171] In certain embodiments, the cells (e.g., the plurality of cells) for use in the present disclosure can be treated with an agent. For example, but not by way of limitation, the agent can be a therapeutic agent. In certain embodiments, methods of the present disclosure can be used in drug screening, e.g., to determine the genomic and / or transcriptional changes associated with a test therapeutic agent, e.g. , a newly identified therapeutic agent. In certain embodiments, methods of the present disclosure can be used in determining the genomic and / or transcriptional changes associated with resistance to a therapeutic agent. Non-limiting examples of such therapeutics comprise polypeptide therapeutics, e.g., antibody -based therapeutics, oligonucleotides, and small molecule therapeutics. In certain embodiments, the therapeutic can be cell cycle regulators, kinase regulators (e.g., kinase inhibitors or activators), receptor regulators (e.g., receptor inhibitors or activators), chemotherapeutics and / or antibodies (e.g., agonist or antagonist antibodies).
[0172] IV. METHODS OF DETECTING VARIANT NUCLEIC ACIDS
[0173] The present disclosure provides methods for detecting variant nucleic acids in a sample, e.g., in a plurality of cells and / or nuclei. In certain embodiments, the variant nucleic acids are RNA, e.g., mRNA. In certain embodiments, the variant nucleic acids are DNA. For example, but not by way of limitation, the present disclosure provides methods for detecting genomic variants in a sample by detecting the mRNAs expressed from a specific genomic region. FIG.
[0174] 1 provides an exemplary method of the present disclosure.
[0175] In certain embodiments, methods of the present disclosure can include analyzing variant nucleic acids in a plurality of cells and / or nuclei. In certain embodiments, methods of the present disclosure can include analyzing variant nucleic acids in a single cell. In certain embodiments, methods of the present disclosure can include the simultaneous analysis of specific target variant nucleic acids and the transcriptome, e.g., in a plurality of cells and / or nuclei. In certain embodiments, methods of the present disclosure can include the simultaneous analysis of specific target variant nucleic acids and the transcriptome of a single cell.
[0176] In certain embodiments, a method of the present disclosure includes providing a sample. In certain embodiments, a sample of the present disclosure can include a plurality of cells and / or nuclei. In certain embodiments, the plurality of cells and / or nucleic can comprise at least about 10, at least about 100, at least about 200, at least about 300, at least about 400, at least about 500, at least about 600, at least about 700, at least about 800, at least about 900, at least about 1000, at least about 5,000, at least about 10,000, at least about 100,000, at least about 1,000,000, at least about 10,000,000, at least about 100,000,000 or at least about
[0177] 516578835.1 25Attorney Ref. No. 00B206.1727
[0178] 1,000,000,000 cells. In certain embodiments, a plurality of cells and / or nuclei can include from about 10 to about 1,000,000,000 cells and / or nuclei, e.g., about 1,000 to about 1,000,000,000 or about 5,000 to about 1,000,000,000. In certain embodiments, the plurality of cells and / or nuclei can comprise from about 100 to about 1,000,000,000 cells and / or nuclei.
[0179] In certain embodiments, the plurality of cells can comprise a variety of cells, e.g, cells of different types, cells of different lineages and / or cells with different genomic mutations. In certain embodiments, the plurality of cells can comprise a variety of cell types pooled together. In certain embodiments, a plurality of cells can comprise at least two or more cell types, at least three or more cell types, at least four or more cell types, at least five or more cell types, at least six or more cell types, at least seven or more cell types, at least eight or more cell types, at least nine or more cell types or at least ten or more cell types. Alternatively, in certain embodiments, the plurality of cells comprises a single cell type, e.g, a plurality of isolated cells. In certain embodiments, the plurality of cells comprises a cell type expressing specific marker, e.g., a cell surface marker (e.g., protein).
[0180] In certain embodiments, the plurality of cells and / or nuclei are obtained from a sample. For example, but not by way of limitation, the plurality of cells and / or nuclei can be isolated from a tissue sample, e.g., a fresh sample, a frozen sample and / or a preserved sample (e.g., a fixed sample). In certain embodiments, the plurality of cells and / or nuclei can be isolated from a fixed sample, e.g., clinical sample. In certain embodiments, the plurality of cells can be enriched for cells of interest to produce an enriched cell sample, which can be subjected to the methods of the present disclosure. Any technique known in the art can be used to enrich for the cells of interest. For example, but not by way of limitation, flow cytometry can be used to enrich for cells of interest to produce an enriched cell sample. In certain embodiments, FACS in combination with antibody labeling can be used to enrich for cells of interest to produce an enriched cell sample.
[0181] In certain embodiments, the sample (e.g., the plurality of cells and / or nuclei) to be analyzed undergoes a sample preparation process prior to performing a method of the present disclosure, e.g., detection of one or more variant target nucleic acids in the sample. In certain embodiments, the sample preparation process can comprise a fixation process and / or a permeabilization process. In certain embodiments, sample preparation comprises a fixation process. In certain embodiments, sample preparation can comprise a permeabilization process. In certain embodiments, sample preparation comprises a fixation process and a permeabilization process. Any technique for fixation of cells and / or nuclei known in the art can be used in the present disclosure. For example, but not by way of limitation, the cells
[0182] 516578835.1 26Attorney Ref. No. 00B206.1727
[0183] and / or nucleic can be contacted with a fixative. In certain embodiments, the fixation process can comprise chemical cross-linking, e.g., by using glutaraldehyde and / or formaldehyde. In certain embodiments, the cells or nuclei can be fixed with an alcohol, e.g., methanol and / or ethanol.
[0184] In certain embodiments, the fixation process comprises contacting a sample (e.g., the plurality of cells and / or nuclei) with a fixative to generate a fixed sample (e.g., a plurality of fixed cells and / or nucleic). Non-limiting examples of fixatives comprise aldehydes (e.g., formaldehyde, paraformaldehyde and glutaraldehyde), imidoesters, N-Hydroxysuccinimide (NHS) esters (e.g., Bis-NHS ester), alcohols (e.g., methanol and ethanol), acetone and acetic acid. In certain embodiments, the fixation process can be performed by exposing the sample to an aldehyde. In certain embodiments, the fixation process can be performed by exposing the sample to formaldehyde. In certain embodiments, the fixation process can be performed by exposing the sample to glutaraldehyde. In certain embodiments, the fixation process can be performed by exposing the sample to paraformaldehyde. In certain embodiments, the fixation process can be performed by exposing the sample to a solution that comprises a noncrosslinking fixative (e.g., an alcohol). In certain embodiments, the sample is fixed in a final fixative concentration (e.g., in v / v, w / w, v / w or w / v) of about 0.1% to about 10%, about 1% to about 10%, about 1% to about 8%, about 2% to about 7%, about 2% to about 6%, about 3% to about 6% or about 3% to about 5%. In certain embodiments, the sample is fixed in a final paraformaldehyde concentration (e.g., in v / v, w / w, v / w or w / v) of about 0.1% to about 10%, about 1% to about 10%, about 1% to about 8%, about 2% to about 7%, about 3% to about 6% or about 3% to about 5%, e.g., about 4%. In certain embodiments, the sample is fixed in a final paraformaldehyde concentration of about 2% to about 6%, e.g., about 4%. In certain embodiments, the sample can be contacted with a fixative for about 1 hour or less.
[0185] In certain embodiments, the cells and / or nuclei can be permeabilized, e.g., the cells can be permeabilized after fixation. For example, but not by way of limitation, the sample can be permeabilized after fixation of the sample and prior to detection of one or more variant target nucleic acids. Techniques for permeabilizing cells are known in the art and one of skill in the art would be able to assess the appropriateness of a particular technique for use in connection with the methods of the present disclosure. Non-limiting examples of reagents for permeabilizing cells comprise detergents (e.g., saponin, Tween-20 and Triton X-100) and fixatives (e.g., acetone, methanol and ethanol). For example, but not by way of limitation, the sample can be permeabilized with an alcohol, e.g., methanol, and / or a detergent, e.g., such as Triton X-100. In certain embodiments, a reagent for permeabilization can be used at a
[0186] 516578835.1 27Attorney Ref. No. 00B206.1727
[0187] concentration (e.g., in v / v, w / w, v / w or w / v) of about 0.1% to about 100%, e.g., about 10% to about 100%, about 20% to about 100%, about 30% to about 100%, about 40% to about 100%, about 50% to about 100%, about 60% to about 100%, about 50% to about 100% or about 70% to about 100%. In certain embodiments, a reagent (e.g., an alcohol, e.g., MeOH) for permeabilization can be used at a concentration of about 50% v / v to about 100% v / v. In certain embodiments, the sample, e.g., fixed sample, can be contacted with a permeabilization reagent for about 1 hour or less, e.g., at a temperature of 25°C or less, e.g., about -20°C. In certain embodiments, fixation and permeabilization can occur simultaneously.
[0188] In certain embodiments, the cells, e.g., cells of a tissue, can be dissociated prior to use in the methods of the present disclosure. For example, but not by way of limitation, the cells can be dissociated to generate a single cell suspension for use in the present disclosure. In certain embodiments, the cells can be dissociated prior to fixing and / or permeabilization of the cells. Methods for dissociating cells, e.g., of a tissue, are known in the art.
[0189] In certain embodiments, a method of the present disclosure includes contacting the cells, e.g., the fixed and / or permeabilized cells, with one or more oligonucleotide probes for specifically binding to the target nucleic acid, e.g., a target variant nucleic acid (referred to herein as “mutation-specific probes”), as shown in step 1 of FIG. 2. For example, but not by way of limitation, a method of the present disclosure includes contacting the cells, e.g., the fixed and / or permeabilized cells, with a plurality of mutation-specific probes.
[0190] In certain embodiments, a plurality of mutation-specific probes, e.g., padlock oligonucleotides (“padlock probes”) or linear oligonucleotides (“linear probes”), for detecting multiple different target nucleic acids can be used in the present disclosure, e.g., as shown in Example 1. For example, but not by way of limitation, each mutation-specific probe, e.g., padlock mutation-specific probe specifically binds to a single target nucleic acid, e.g., a single target variant nucleic acid. In certain embodiments, the cells are contacted with two or more, three or more, four or more, five or more, six or more, seven or more, eight or more, nine or more or ten mutation-specific probes, e.g., where each probe specifically binds to different target nucleic acids. For example, but not by way of limitation, two or more padlock mutationspecific probes, three or more padlock mutation-specific probes, four or more padlock mutation-specific probes, five or more padlock mutation-specific probes, six or more padlock mutation-specific probes, seven or more padlock mutation-specific probes, eight or more padlock mutation-specific probes, nine or more padlock mutation-specific probes or ten or more padlock mutation-specific probes can be used in the present disclosure, where each padlock mutation-specific probe specifically binds to a single target nucleic acid. In certain
[0191] 516578835.1 28Attorney Ref. No. 00B206.1727
[0192] embodiments, two or more linear mutation-specific probes, three or more linear mutationspecific probes, four or more linear mutation-specific probes, five or more linear mutationspecific probes, six or more linear mutation-specific probes, seven or more linear mutationspecific probes, eight or more linear mutation-specific probes, nine or more linear mutationspecific probes or ten or more linear mutation-specific probes can be used in the present disclosure, where each linear mutation-specific probe specifically binds to a single target nucleic acid.
[0193] FIG. 2 and FIGs. 3A-3B provide exemplary schematics of a mutation-specific probe that hybridizes to the target variant nucleic acids. In certain embodiments, the mutationspecific probe is a padlock probe that hybridizes to the target variant nucleic acid (e.g., as shown in FIG. 3A). In certain embodiments, the mutation-specific probe is a pair of linear probes that hybridize to the target variant nucleic acid (e.g., as shown in FIG. 3B). In certain embodiments, the mutation-specific probe (e.g., the padlock probe or the pair of linear probes) includes a first homology site (e.g., a right homology site (RHS)) and a second homology site (e.g., a left homology site (LHS) (also referred to herein as an LFS as shown in FIGs.3A-3B)) that are complementary to the target site on the target nucleic acid to promote the hybridization of the mutation-specific probe to the target nucleic acid as shown in FIGs. 3A-3B. In certain embodiments where the mutation-specific probe is a pair of linear probes, one probe of the pair includes the first homology site (e.g., an RHS) and the second probe of the pair includes the second homology site (e.g., an LHS (or LFS)) as shown in FIG. 3B. In certain embodiments, the first homology region is complementary to a first sequence of the target nucleic acid and the second homology region is complementary to a second sequence of the target nucleic acid. In certain embodiments, the first homology region is about 5 to about 100 nucleotides in length, e.g., from about 15 to about 75 nucleotides, from about 15 to about 50 nucleotides or from about 20 to about 30 nucleotides in length. In certain embodiments, the first homology region is at least about 25 nucleotides in length. In certain embodiments, the second homology region is about 5 to about 100 nucleotides in length, e.g., from about 15 to about 75 nucleotides, from about 15 to about 50 nucleotides or from about 20 to about 30 nucleotides in length. In certain embodiments, the second homology region is at least about 25 nucleotides in length. In certain embodiments, the first homology region and / or second homology region has a Tm(melting temperature) of about 60°C or higher. In certain embodiments, the first homology region and / or second homology region has GC content from about 30% to about 80%, e.g., about 40% to about 80%, about 45% to about 80%, about 50% to about 80%, about 30% to about 75%,
[0194] 516578835.1 29Attorney Ref. No. 00B206.1727
[0195] about 30% to about 70%, about 30% to about 65%, about 30% to about 60%, about 30% to about 55%, about 30% to about 50% or about 35% to about 60%.
[0196] In certain embodiments, the mutation-specific probe (e.g., the padlock probe or one or more probes of a pair of linear probes) further includes one or more of the following nucleotide sequences: a constant region sequence, a spacer sequence, a capture sequence (also referred to herein as “pCSl”), a probe barcode (probe BC) and pRead RS (pR2S), as shown in FIGs. 3A-3B and Table 2. In certain embodiments, the constant region, the spacer and / or the probe barcode can include a nucleotide sequence that can function as a primer binding region (e.g., for performing an amplification process). In certain embodiments, the spacer nucleotide sequence includes a nucleotide sequence that can function as a primer binding region. In certain embodiments, the nucleotide sequence that can function as a primer binding region comprises the nucleotide sequence GCAACGACTCCACACTCATA (SEQ ID NO: 1), as shown in Table 2. In certain embodiments, the capture sequence is a sequence that allows for the capture of the mutation-specific probe hybridized to the target nucleic acid in a lOx Genomics system, as shown in FIGs. 3A-3B.
[0197] In certain embodiments, the nucleotide sequence that can function as a primer binding region comprises a nucleotide sequence that has about 75%, about 80%, about 85%, about 90%, about 95%, about 96%, about 97%, about 98%, about 99% or about 100% homology to the nucleotide sequence GCAACGACTCCACACTCATA (SEQ ID NO: 1). In certain embodiments, the nucleotide sequence that can function as a primer binding region comprises the nucleotide sequence GCAACGACTCCACACTCATA (SEQ ID NO: 1).
[0198] In certain embodiments, the capture sequence comprises a nucleotide sequence that has about 75%, about 80%, about 85%, about 90%, about 95%, about 96%, about 97%, about 98%, about 99% or about 100% homology to SEQ ID NO: 3. In certain embodiments, the capture sequence comprises the nucleotide sequence of SEQ ID NO: 3.
[0199] In certain embodiments, the constant region comprises a nucleotide sequence that has about 75%, about 80%, about 85%, about 90%, about 95%, about 96%, about 97%, about 98%, about 99% or about 100% homology to SEQ ID NO: 2. In certain embodiments, the constant region comprises the nucleotide sequence of SEQ ID NO: 2.
[0200] In certain embodiments, the pR2S sequence comprises a nucleotide sequence that has about 75%, about 80%, about 85%, about 90%, about 95%, about 96%, about 97%, about 98%, about 99% or about 100% homology to SEQ ID NO: 4. In certain embodiments, the pR2S sequence comprises the nucleotide sequence of SEQ ID NO: 4.
[0201] 516578835.1 30Attorney Ref. No. 00B206.1727
[0202] In certain embodiments, a padlock mutation-specific probe of the present disclosure comprises (i) a left homology site, (ii) pR2S, (iii) a spacer sequence, (iv) a capture sequence, (v) a probe barcode sequence, (vi) a constant region and (vii) a right homology site, as shown in FIG. 3A. In certain embodiments, a padlock mutation-specific probe of the present disclosure comprises the following sequences in the 3’ to 5’ orientation: (i) a left homology site, (ii) a spacer sequence, (iii) a capture sequence, (iv) a probe barcode sequence, (v) a constant region and (vi) a right homology site. In certain embodiments, a padlock mutationspecific probe of the present disclosure comprises the following sequences in the 3’ to 5’ orientation: (i) a left homology site, (ii) pR2S, (iii) a spacer sequence, (iv) a capture sequence, (v) a probe barcode sequence, (vi) a constant region and (vii) a right homology site. In certain embodiments, the first homology region is complementary to a first sequence of the target nucleic acid and the second homology region is complementary to a second sequence of the target nucleic acid. In certain embodiments, the spacer sequence comprises the nucleotide sequence of SEQ ID NO: 1. In certain embodiments, the constant region comprises the nucleotide sequence of SEQ ID NO: 2. In certain embodiments, the capture sequence comprises the nucleotide sequence of SEQ ID NO: 3. In certain embodiments, the pR2S sequence comprises the nucleotide sequence of SEQ ID NO: 4.
[0203] In certain embodiments, a pair of linear mutation-specific probes includes a first linear probe and a second linear probe. In certain embodiments, the first linear probe comprises (i) a left homology site, (ii) pR2S and (iii) a spacer sequence. In certain embodiments, the second linear probe comprises (i) a capture sequence (also referred to herein as “pCSl”), (ii) a probe barcode sequence, (iii) a constant region and (vii) a right homology site, as shown in FIG. 3B.
[0204] In certain embodiments, the first linear probe of the present disclosure comprises the following sequences in the 3’ to 5’ orientation: (i) a left homology site and (ii) a spacer sequence. In certain embodiments, the first linear probe of the present disclosure comprises the following sequences in the 3’ to 5’ orientation: (i) a left homology site, (ii) pR2S and (iii) a spacer sequence. In certain embodiments, the second linear probe of the present disclosure comprises the following sequences in the 3’ to 5’ orientation: (i) a capture sequence (also referred to herein as “pCSl”), (ii) a probe barcode sequence, (iii) a constant region and (vii) a right homology site. In certain embodiments, the first homology region is complementary to a first sequence of the target nucleic acid and the second homology region is complementary to a second sequence of the target nucleic acid. In certain embodiments, the spacer sequence comprises the nucleotide sequence of SEQ ID NO: 1. In certain embodiments, the constant region comprises the nucleotide sequence of SEQ ID NO: 2. In certain embodiments, the
[0205] 516578835.1 31Attorney Ref. No. 00B206.1727
[0206] capture sequence comprises the nucleotide sequence of SEQ ID NO: 3. In certain embodiments, the pR2S sequence comprises the nucleotide sequence of SEQ ID NO: 4.
[0207] In certain embodiments, a mutation-specific probe for use in the present disclosure can be about 5 to about 200 nucleotides in length, e.g., about 5 to about 150 nucleotides in length, about 5 to about 100 nucleotides in length, about 5 to about 50 nucleotides in length, about 10 to about 150 nucleotides in length, about 20 to about 100 nucleotides in length or about 10 to about 100 nucleotides in length.
[0208] In certain embodiments, the one or more mutation-specific probes comprise a gap of one or more nucleotides, e.g., as represented by a star in FIG.2 and a triangle in FIGs.3A-3B.
[0209] For example, but not by way of limitation, a mutation-specific probe for use in the present disclosure comprises gap of one or more nucleotides located between the RHS and the LHS. For example, but not by way of limitation, where the mutation-specific probe is a padlock probe, the gap can be present between the RHS and LHS of the padlock probe (e.g., between the 5’ end and 3’ end of the padlock probe) when hybridized to the target nucleic acid, e.g., as shown in FIG. 3A. In certain embodiments where the mutation-specific probe is a pair of linear probes, the gap can be present between the two linear probes. In certain embodiments, the gap can be present between the 3’ end of the first linear probe and the 5’ end of the second linear probe when hybridized to the target nucleic acid, e.g., as shown in FIG. 3B.
[0210] In certain embodiments, the gap between the RHS and the LHS (e.g., in the mutationspecific probe and / or generated when the mutation-specific probe hybridizes to the target nucleic acid) corresponds to a single nucleotide polymorphism (SNP) site in the target nucleic acid. In certain embodiments, the gap between the RHS and the LHS (e.g., in the mutationspecific probe and / or generated when the mutation-specific probe hybridizes to the target nucleic acid) corresponds to a single nucleotide variation (SNV) site in the target nucleic acid.
[0211] In certain embodiments, a mutation-specific probe for use in the present disclosure comprises a gap, e.g., that corresponds to the variant sequence in the target nucleic acid. In certain embodiments, a mutation-specific probe, e.g., a padlock probe, for use in the present disclosure comprises a gap between the RHS and LHS, e.g., that corresponds to the variant sequence in the target nucleic acid. In certain embodiments, a mutation-specific probe, e.g., a padlock probe, for use in the present disclosure forms a gap (e.g., between the RHS and LHS) when hybridized to the target nucleic acid (as shown in FIG. 3B). In certain embodiments, a pair of linear probes forms a gap (e.g., between the RHS and LHS) when hybridized to the target nucleic acid (as shown in FIG. 3A).
[0212] 516578835.1 32Attorney Ref. No. 00B206.1727
[0213] In certain embodiments, the gap can be from about 1 to about 1,000 nucleotides in length, e.g., about 1 to about 900 nucleotides in length, about 1 to about 800 nucleotides in length, about 1 to about 700 nucleotides in length, about 1 to about 600 nucleotides in length, about 1 to about 500 nucleotides in length, about 1 to about 400 nucleotides in length, about 1 to about 300 nucleotides in length, about 1 to about 200 nucleotides in length, about 1 to about 100 nucleotides in length, about 1 to about 50 nucleotides in length, about 1 to about 40 nucleotides in length, about 1 to about 30 nucleotides in length, about 1 to about 200 nucleotides in length, about 1 to about 10 nucleotides in length or about 1 to about 5 nucleotides in length. In certain embodiments, a mutation-specific probe for use in the present disclosure comprises a one nucleotide gap (or forms a one nucleotide gap when hybridized to the target nucleic acid) that corresponds to the nucleotide that is variant in the target nucleic acid. In certain embodiments, a mutation-specific probe for use in the present disclosure forms a one nucleotide gap when hybridized to the target nucleic acid that corresponds to the nucleotide that is variant in the target nucleic acid. In certain embodiments, the one or more mutationspecific probes comprise a two-nucleotide gap (or forms a two-nucleotide gap when hybridized to the target nucleic acid) that corresponds to or includes the nucleotides that are variant in the target nucleic acid. In certain embodiments, the one or more mutation-specific probes form a two-nucleotide gap when hybridized to the target nucleic acid that corresponds to or includes the nucleotides that are variant in the target nucleic acid. In certain embodiments, the one or more mutation-specific probes comprise a three-nucleotide gap (or forms a three-nucleotide gap when hybridized to the target nucleic acid) that corresponds to or includes the nucleotides that are variant in the target nucleic acid. In certain embodiments, the one or more mutationspecific probes form a three-nucleotide gap when hybridized to the target nucleic acid that corresponds to or includes the nucleotides that are variant in the target nucleic acid. In certain embodiments, the one or more mutation-specific probes comprise a four-nucleotide gap (or forms a four-nucleotide gap when hybridized to the target nucleic acid) that corresponds to or includes the nucleotides that are variant in the target nucleic acid. In certain embodiments, the one or more mutation-specific probes form a four-nucleotide gap when hybridized to the target nucleic acid that corresponds to or includes the nucleotides that are variant in the target nucleic acid. In certain embodiments, the one or more mutation-specific probes comprise a five-nucleotide gap (or forms a five-nucleotide gap when hybridized to the target nucleic acid) that corresponds to or includes the nucleotides that are variant in the target nucleic acid. In certain embodiments, the one or more mutation-specific probes form a five-nucleotide gap when hybridized to the target nucleic acid that corresponds to or includes the nucleotides that are
[0214] 516578835.1 33Attorney Ref. No. 00B206.1727
[0215] variant in the target nucleic acid. In certain embodiments, the one or more mutation-specific probes comprise a one to about five nucleotide gap (or forms a one to about five nucleotide gap when hybridized to the target nucleic acid). In certain embodiments, the one or more mutationspecific probes form a one to about five nucleotide gap when hybridized to the target nucleic acid.
[0216] In certain embodiments, hybridization of the mutation-specific probes to the target nucleic acids can occur in a hybridization buffer for a period of about 1 hour to about 24 hours, e.g., from about 2 hours to about 20 hours, from about 2 hours to about 16 hours or from about 2 hours to about 12 hours. In certain embodiments, the mutation-specific probes (e.g., the mutation-specific padlock probes) can be used at a concentration from about 100 pM to about 100 pM, e.g., about 100 pM to about 10 pM, about 100 pM to about 1,000 nM, about 100 pM to about 100 nM, about 100 pM to about 10 nM, about 100 pM to about 1 nM or about 1 nM to about 1,000 nM. In certain embodiments, the mutation-specific probes (e.g., the mutationspecific padlock probes) can be used at a concentration from about 1 nM to about 1,000 nM, e.g., from about 1 nM to about 900 nM, from about 1 nM to about 800 nM, from about 1 nM to about 700 nM, from about 1 nM to about 600 nM or from about 1 nM to about 500 nM. In certain embodiments, the concentration of the mutation-specific probes (e.g., the mutationspecific padlock probes) is from about 200 nM to about 700 nM.
[0217] In certain embodiments, a method of the present disclosure can comprise a gap filling process, e.g., to fill in the gap of the mutation-specific padlock or linear probe that specifically hybridizes to the target nucleic acid. FIG. 2 provides an exemplary gap filling process for use in the present disclosure. In certain embodiments, gap filling is performed by contacting the sample with a composition that comprises a polymerase and reversible terminator nucleotides. A reversible terminator nucleotide is a modified deoxynucleotide triphosphate (dNTP) or dNTP analog that contains a removable blocking group that ensures that only a single base can be added by a polymerase enzyme to the 3’ end of a growing nucleic acid. Non-limiting examples of reversible terminator molecules are disclosed in Chen et al., Genomic Proteomics Bioinformatics 11 :34-40 (2013), the contents of which are incorporated by reference herein in its entirety. Figures 1 and 2 of Chen et al. (2013) provide exemplary reversible terminator nucleotides that can be used in the present disclosure. In certain embodiments, the reversible terminator nucleotides include 3 ’-blocked reversible terminator nucleotides. For example, but not by way of limitation, the reversible terminator nucleotide comprises a nucleobase, a sugar moiety and a cleavable blocking group, e.g., a cleavable 3 ’-blocking group. Non-limiting examples of 3’-blocked reversible terminator nucleotides include 3’-O-azidomethyl reversible
[0218] 516578835.1 34Attorney Ref. No. 00B206.1727
[0219] terminators, 3’-O-allyl reversible terminators and 3’-O-NH2 reversible terminators. In certain embodiments, the reversible terminator nucleotides include 3 ’-unblocked reversible terminator nucleotides. Non-limiting examples of 3 ’-unblocked reversible terminator nucleotides include 3 ’-unblocked reversible terminator nucleotides referred to as “Lightning terminator” nucleotides (see Bowers et al. Nat Methods. 6:593-595 (2009)) and reversible terminator nucleotides comprising a tethered inhibitor referred to as “Virtual Terminator” nucleotides (see Gardener et al. Nucleic Acids Res. 40:7404-7415 (2012)). In certain embodiments, the reversible terminator nucleotides include a label, e.g., fluorescent label, linked to the base of the nucleotide by a cleavable linker. In certain embodiments, the reversible terminator nucleotides for use in the present disclosure do not include a label, e.g., a fluorescent label. As shown in step 2 of FIG.2, the reversible terminator nucleotide that is incorporated into the gap of the mutation-specific probe depends on the nucleotide sequence of the target nucleic acid and whether the target nucleic acid is the wild type nucleic acid or a variant nucleic acid.
[0220] In certain embodiments, a gap filling process can include contacting the cell and / or nuclei comprising the mutation-specific probe hybridized to the target nucleic acid with reversible terminator nucleotides, e.g., 3 ’-blocked reversible terminator nucleotides, and a polymerase (e.g., a reverse transcriptase) for a sufficient period of time for a reversible terminator nucleotide to be incorporated into the gap position of the mutation-specific probe. In certain embodiments, the method can further include removal of the blocking group, e.g., the 3’-0 blocking group of the reversible terminator nucleotide, and / or the removal of the fluorescent tag of the reversible terminator nucleotide. As shown in Example 1 and FIG. 7, the use of reversible terminator nucleotides in the gap filling process as compared to unblocked nucleotides resulted in improved accuracy in mutation detection, reduced false signals, improved signal to noise and improved mapping rates. Additionally, the use of reversible terminator nucleotides enables the filling of a gap longer than a single nucleotide, e.g., that is formed when a mutation-specific probe is hybridized to the target nucleic acid. Further, detection of variant nucleic acids, such as variant mRNAs, in clinical samples that have undergone fixation is challenging due to compromised mRNA integrity. However, as demonstrated in Example 1, the use of the disclosed mutation-specific probes and reversible terminator nucleotides in the gap filling process enables highly sensitive and accurate detection of mRNA variants despite these limitations.
[0221] In certain embodiments, the conditions for removal can be selected by one of ordinary skill in the art based on the descriptions provided herein, the chemical identity of the blocking group to be removed and nucleic acid chemistry principles known in the art. For example, but
[0222] 516578835.1 35Attorney Ref. No. 00B206.1727
[0223] not by way of limitation, removal of the blocking group can occur by enzymatic cleavage or chemical cleavage (e.g., hydrolysis). In certain embodiments, the blocking group can be removed by contacting the reversible terminator nucleotide with a reducing agent. Nonlimiting examples of reducing agents include dithiothreitol (DTT), or a phosphine reagent such as tris(2-carboxyethyl)phosphine (TCEP), tris(hydroxymethyl)phosphine (THP) or tris(hydroxypropyl) phosphine. Non-limiting examples of 3’-0 reversible blocking groups that can be cleaved by contact with a reducing agent include a 3’-O-azidomethyl group. In certain embodiments, the blocking group is photolabile and can be removed by application of light, e.g., UV light. Non-limiting examples of 3’-0 reversible blocking groups that can be cleaved by UV light include nitrobenzyl. In certain embodiments, the blocking group can be removed by contacting the reversible terminator nucleotide with a transition metal catalyzed reaction using, e.g., an aqueous palladium (Pd) solution. Non-limiting examples of 3’-0 reversible blocking groups that can be cleaved by contacting with an aqueous Pd solution include allyl. In certain embodiments, the blocking group can be removed by contacting the reversible terminator nucleotide with an aqueous nitrite solution. In certain embodiments, the blocking group can be removed from the reversible terminator nucleotide by changing the pH of the solution or mixture containing the incorporated reversible terminator nucleotide. In certain embodiments, the blocking group can be removed by contacting the reversible terminator nucleotide with acid or a low pH buffered aqueous solution. Non-limiting examples of 3’-0 reversible blocking groups that can be cleaved with acid include methoxymethyl. In certain embodiments, the blocking group can be removed by contacting the reversible terminator nucleotide with base or a high pH buffered aqueous solution. Non-limiting examples of 3’-0 reversible blocking groups that can be cleaved by contacting with an aqueous buffered (pH 5.5) solution of sodium nitrite include aminoalkoxyl. In certain embodiments, removal of the blocking group, e.g., the 3’-0 blocking group of the reversible terminator nucleotide, in the presently disclosed method includes contacting the incorporated reversible terminator nucleotide with TCEP to cleave the linker coupled to the fluorophore and to remove the 3’-O-azidom ethyl group to regenerate a 3 ’-OH.
[0224] In certain embodiments where the gap in the probe is greater than one nucleotide in length, this gap filling process can be repeated in a stepwise approach until the gap is filled. In certain embodiments, for each cycle, the nucleotide or nucleotide analogue with a cleavable blocking group (e.g., reversible terminator nucleotide) is incorporated by a polymerase (e.g, a reverse transcriptase), extending the 3’ end of the mutation-specific probe, e.g, padlock probe, by one base, and unincorporated reversible terminator nucleotides are washed away, the
[0225] 516578835.1 36Attorney Ref. No. 00B206.1727
[0226] blocking group is then removed from the incorporated reversible terminator nucleotide, allowing the next cycle of incorporating a second nucleotide with a blocking group (e.g., second reversible terminator nucleotide) to proceed. For example, but not by way of limitation, a gap filling process of a two-nucleotide gap in the mutation-specific probe can include (i) contacting the cell and / or nuclei comprising the mutation-specific probe with reversible terminator nucleotides, e.g., 3 ’-blocked reversible terminator nucleotides, and a polymerase (e.g., a reverse transcriptase) for a sufficient period of time for a reversible terminator nucleotide to be incorporated into the first gap position of the probe, (ii) removing the blocking group, e.g, the 3’-0 blocking group, of the reversible terminator nucleotide and / or the removal of the fluorescent tag of the reversible terminator nucleotide, (iii) contacting the cell and / or nuclei comprising the mutation-specific probe having the first gap position filled with reversible terminator nucleotides, e.g, a 3 ’-blocked reversible terminator nucleotides, and a polymerase (e.g., a reverse transcriptase) for a sufficient period of time for a reversible terminator nucleotide to be incorporated into the second gap position of the probe, and (iv) removing the blocking group, e.g., the 3’-0 blocking group of the reversible terminator nucleotide and / or the removal of the fluorescent tag of the reversible terminator nucleotide incorporated in the second gap position. This process can continue until all gaps with the mutation-specific probe are filled. For example, but not by way of limitation, this process can continue until all nucleotide positions within the gap of the mutation-specific probe (or the gap formed by the mutation-specific probe when hybridized to the target nucleic acid) are filled. In certain embodiments, the gap filling process can occur for a period of about 1 hour to about 24 hours, e.g., from about 1 hours to about 20 hours, from about 10 minutes to about 16 hours, from about 10 minutes to about 12 hours, from about 10 minutes to about 10 hours, from about 10 minutes to about 5 hours, from about 10 minutes to about 2 hours or from about 10 minutes to about 1 hour. In certain embodiments, the gap filling process can occur at a temperature ranging from about 10°C to 60°C, e.g., at 50°C.
[0227] In certain embodiments, a method of the present disclosure can further include a ligation process after the gap filling process. In certain embodiments, the mutation-specific padlock probes can be converted into a circular DNA molecule by ligation upon hybridization to a target nucleic acid. Alternatively, the mutation-specific probes, e.g., a pair of linear mutation-specific probes, can be converted into a single continuous linear probe molecule by ligation upon hybridization to a target nucleic acid. In certain embodiments, ligation is performed using a ligase that ligates single stranded DNA, e.g., SplintR ligase. In certain embodiments, ligation is performed using a ligase that ligates single stranded DNA, e.g.,
[0228] 516578835.1 37Attorney Ref. No. 00B206.1727
[0229] Ampligase ligase. Additional disclosure regarding the use of padlock probes is provided in Sountoulidis et al., PLoS Biology 18(ll):e3000675 (2020), the contents of which is herein incorporated by reference. In certain embodiments, ligation using a ligase, e.g., ligation with the SplintR ligase, can be performed following the hybridization and gap-filling of the mutation-specific probes to the target nucleic acids. In certain embodiments, ligation can occur for a period of about 1 hour to about 24 hours, e.g., from about 1 hour to about 20 hours, from about 1 hour to about 16 hours, from about 1 hour to about 12 hours, from about 4 hours to about 20 hours or from about 4 hours to about 16 hours. In certain embodiments, ligation can occur for a period of about 1 hour to about 24 hours. In certain embodiments, ligation can occur for a period of about 1 hour to about 20 hours. In certain embodiments, ligation can occur for a period of about 1 hour to about 16 hours. In certain embodiments, ligation can occur for a period of about 1 hour to about 12 hours. In certain embodiments, ligation can occur for a period of about 1 hour to about 6 hours. In certain embodiments, ligation can occur at a temperature ranging from about 4°C to 60°C, e.g. , at 4°C or 25°C. In certain embodiments, ligation can occur at a temperature of about 25°C for about 4 hours. In certain embodiments, ligation can occur at a temperature of about 4°C for about 24 hours.
[0230] In certain embodiments, a method of the present disclosure further includes contacting the individual cells and / or nuclei that have target nucleic acids hybridized to the mutationspecific probes with a plurality of particles. In certain embodiments, a plurality of particles can be contacted with the plurality of cells or nuclei that have target nucleic acids hybridized to the mutation-specific probes. In certain embodiments, a plurality of particles, e.g., beads, include about 5,000 to about 10,000,000 particles. In certain embodiments, the particles that are combined with the cells or nuclei can be glass, plastic, gel or metal particles. In certain embodiments, the particles can be beads, e.g., microbeads. In certain embodiments, the particles are gel beads, e.g., gel microbeads. In certain embodiments, the particles can be any shape, e.g., the particles can have a spherical, non- spherical, oval, oblong, amorphous, circular or cylindrical shape. In certain embodiments, the particles can have a diameter of about 0.5 to about 500 pm. In certain embodiments, the particles have a diameter less than about 0.5 pm, less than about 1.0 pm, less than about 1.5 pm, less than about 2.0 pm, less than about 5.0 pm, less than about 10.0 pm, less than about 20.0 pm, less than about 30.0 pm, less than about 40.0 pm, less than about 50.0 pm, less than about 60 pm, less than about 70 pm, less than about 80 pm, less than about 90 pm, less than about 100 pm, less than about 250 pm or less than about 500 pm.
[0231] 516578835.1 38Attorney Ref. No. 00B206.1727
[0232] In certain embodiments, a polynucleotide comprising a barcode (referred to herein as a “barcode polynucleotide”) is coupled to the particles, e.g., beads. In certain embodiments, the barcode polynucleotide includes a barcode (shown as the 10X barcode in FIGs. 3A-3B) and a capture sequence that is complementary to the capture sequence of the mutation-specific probes (e.g., shown as pCSl in FIGs.3A-3B). In certain embodiments, the barcode polynucleotide is coupled to the particles, e.g., beads, using a linker. In certain embodiments, the barcode polynucleotide can further include a unique molecular identifier (UMI) sequence (e.g., a 12 nucleotide UMI) and / or a pReadlT sequence (e.g., that includes a sequencing primer) (e.g., as shown in FIGs. 3A-3B). In certain embodiments, the barcode polynucleotide coupled to the particle, e.g., bead, include a UMI sequence and a pReadlT sequence. In certain embodiments, each particle is coupled to a unique barcode polynucleotide to allow for identification of nucleic acids obtained from an individual cell.
[0233] In certain embodiments, the method can further comprise partitioning individual particles and one or more of the cells or nuclei that have target nucleic acids hybridized to the mutation-specific probes into a compartment. In certain embodiments, each compartment comprises one particle and one or more cells or nuclei that have target nucleic acids hybridized to the mutation-specific probes. In certain embodiments, each compartment comprises one bead and one cell or nuclei that have target nucleic acids hybridized to the mutation-specific probes. In certain embodiments, each compartment comprises no more than one bead and one cell or nuclei that have target nucleic acids hybridized to the mutation-specific probes.
[0234] In certain embodiments, the compartment is an emulsion. For example, but not by way of limitation, the compartment is an emulsion droplet. In certain embodiments, individual particles, e.g., beads, and one or more of the cells or nuclei can be partitioned into emulsion droplets. In certain embodiments, partitioning the individual particles and the one or more cells or nuclei into emulsion droplets can comprise bringing the plurality of particles from a first aqueous phase and the cells or nuclei from a second aqueous phase in contact with another phase, e.g., a non-aqueous phase, that is immiscible with the first and / or second aqueous phase to form emulsion droplets. Alternatively, partitioning the individual particles and the one or more cells or nuclei into emulsion droplets can comprise bringing a first aqueous phase comprising the plurality of particles and the cells or nuclei in contact with another phase, e.g., a non-aqueous phase, that is immiscible with the first aqueous phase to form emulsion droplets.
[0235] In certain embodiments, the emulsion droplets can be generated by providing the cells and / or nucleic in a first fluid, e.g., a first aqueous phase, and combining the first fluid with a second fluid, e.g., a second aqueous phase or a non-aqueous phase, and shearing the fluids to
[0236] 516578835.1 39Attorney Ref. No. 00B206.1727
[0237] generate a plurality of emulsion droplets that contain an individual particle and one or more of the cells or nuclei. In certain embodiments, shearing the fluids can be performed using any known method, technique or device for mixing solutions. For example, but not by way of limitation, shearing the fluids can include vortexing, shaking, flicking, stirring and / or pipetting. In certain embodiments, shearing the fluids includes vortexing the fluids to generate emulsion droplets.
[0238] In certain embodiments, the emulsion droplets can be generated using any emulsion droplet generating device. In certain embodiments, the emulsion droplet generating device can be a microfluidic device. For example, but not by way of limitation, droplets can be generated on a Chromium™ platform commercialized by lOx Genomics. In certain embodiments, a first aqueous phase comprising the barcode polynucleotide carrying beads is flowed through a channel segment and a second aqueous phase comprising the cells or nuclei is flowed through a second channel segment towards a channel junction. A partitioning fluid (e.g., oil) is introduced into the channel junction from one or more side channels, and the combined streams are flowed into an outlet channel. Within the channel junction, the two aqueous streams are combined with the partitioning oil, and partitioned into droplets that contain co-partitioned nucleic or cells and beads into emulsion droplets (referred to herein as “GEMs”) (FIG. 1). In certain embodiments, controlling the flow characteristics of each of the fluids combining at the channel junction and controlling the geometry of the channel junction, one can achieve a desired occupancy level of beads, cells (or nuclei) or both, within the droplets that are generated. Additional disclosure regarding microfluidic devices for use in the present disclosure is provided in WO 2017 / 096158 and U.S. Patent No. 11,193,122, the contents of each which are incorporated herein in their entirety.
[0239] In certain embodiments, partitioning the individual particles and the one or more cells or nuclei can result in the generation of a plurality of emulsion droplets. In certain embodiments, the methods of the present disclosure can comprise the generation of at least about 1,000 droplets, at least about 2,000 droplets, at least about 3,000 droplets, at least about 4,000 droplets, at least about 5,000 droplets, at least about 6,000 droplets, at least about 7,000 droplets, at least about 8,000 droplets, at least about 9,000 droplets, at least about 10,000 droplets, at least about 20,000 droplets, at least about 30,000 droplets, at least about 40,000 droplets, at least about 50,000 droplets, at least about 60,000 droplets, at least about 70,000 droplets, at least about 80,000 droplets, at least about 90,000 droplets, at least about 100,000 droplets, at least about 200,000 droplets, at least about 300,000 droplets, at least about 400,000 droplets, at least about 500,000 droplets, at least about 600,000 droplets, at least about 700,000
[0240] 516578835.1 40Attorney Ref. No. 00B206.1727
[0241] droplets, at least about 800,000 droplets, at least about 900,000 droplets or at least about 1,000,000 droplets. In certain embodiments, from about 5,000 to about 1,000,000 droplets are generated.
[0242] In certain embodiments, other reagents can be co-partitioned into the emulsion droplets. In certain embodiments, such reagents can be used to incorporate the UMI sequence, barcode and / or pReadlT sequence from the barcode polynucleotide into the mutation-specific probes (e.g., the mutation-specific probes that have been gap filled) that are bound to target nucleic acids, e.g., as shown in FIGs. 3A-3B. For example, but not by way of limitation, the reagents can comprise polymerases, reverse transcriptases, nucleoside triphosphates or NTP analogues, primers, cofactors, endonucleases, lysis reagents, dyes, markers or labels. In certain embodiments, additional reagents can include proteases to remove proteins bound to the nucleic acids of the cell or nuclei and / or transposases or transposomes to fragment or insert a known sequence into the nucleic acids of a cell or nuclei.
[0243] In certain embodiments, the method can further comprise incorporating the UMI sequence, barcode and / or pReadlT sequence from the barcode polynucleotide into the mutation-specific probes that are bound to target nucleic acids to generate barcoded target nucleic acids (e.g., barcoded target variant nucleic acids), e.g., as shown in FIGs. 3A-3B (the pReadlT sequence is also referred to as the “pRead TT” sequence in the figures). In certain embodiments, incorporating the UMI sequence, barcode and / or pReadlT sequence of the barcode polynucleotide into the mutation-specific probes (e.g., the mutation-specific probes that have been gap filled) occurs within the droplet, e.g., using the reagents that are copartitioned into the droplets. Any suitable nucleic acid amplification method known in the art can be used to incorporate the UMI sequence, barcode and / or pReadlT sequence into the mutation-specific probes. Non-limiting examples of such amplification methods include polymerase chain reaction (PCR), reverse transcriptase PCR, real-time PCR, rolling circle amplification (RCA), self-sustained sequence replication (3 SR), nucleic acid sequence-based amplification (NASBA), strand displacement amplification (SDA), transcription-mediated amplification (TMA), single primer isothermal amplification (SPIA), helicase-dependent amplification (HDA), loop mediated amplification (LAMP), recombinase-polymerase amplification (RPA), nicking enzyme amplification reaction (NEAR), nicking endonuclease assisted nanoparticle activation (NENNA) and ligase chain reaction (LCR). In certain embodiments, the amplification process is PCR. In certain embodiments, PCR is used to incorporate the UMI sequence, barcode and / or pReadlT sequence into the mutation-specific probes. Fakruddin et al., J. Pharm. Bioallied. Sci. 5(4): 245-252 (2013) and Yan et al., Mol.
[0244] 516578835.1 41Attorney Ref. No. 00B206.1727
[0245] BioSyst. 10:970-1003 (2014) disclose additional amplification methods for use in the present disclosure, the contents of each of which are disclosed in their entirety herein.
[0246] In certain embodiments, the capture sequence, e.g., present in the barcode polynucleotide coupled to the particle, is hybridized to the capture sequence of the probe and is extended by a polymerase, e.g., to generate a barcoded mutant-specific nucleic acid as shown in FIGs.3A-3B (also referred to herein as a pre-amplification mutation-specific nucleic acid). For example, and not by way of limitation, the barcoded mutant-specific nucleic acid can include one or more of the following: pReadlT, 10X BC, UMI, pCSl, probe BC, constant region, RHS, LHS, pRead 2S and spacer as shown in FIGs. 3A-3B (LHS is referred to as “LFS” in the pre-amplification mutation fragments, sample index PCR and final library nucleic acids). In certain embodiments, the barcode mutant-specific nucleic acid includes pReadlT, 10X BC, UMI, pCSl, probe BC, constant region, RHS, LHS, pRead 2S and spacer. In certain embodiments, the variant nucleotide(s) is present between the RHS and LHS in the barcoded mutant-specific nucleic acid.
[0247] In certain embodiments, the particles can be dissolved to release the polynucleotides coupled to the particles in the compartments prior to polymerase extension. In certain embodiments, the particles can be dissolved or degraded using a reducing agent, changing the temperature, e.g., heating the droplets, changing the pH and / or exposure to light. In certain embodiments, the cells can be lysed within the partitions prior to amplification. In certain embodiments, PCR is used to incorporate the UMI sequence, barcode and / or pReadlT sequence into the mutant-specific probes to generate barcoded target nucleic acids (e.g., barcoded target variant nucleic acids). For example, and not by way of limitation, the barcoded target variant nucleic acids can include one or more of the following: pReadlT, 10X BC, UMI, pCSl, probe BC, constant region, RHS, LHS, pRead 2S and spacer as shown in FIGs. 3A-3B (LHS is referred to as “LFS” in the pre-amplification mutation fragments, sample index PCR and final library nucleic acids). In certain embodiments, the barcoded target variant nucleic acid includes pReadlT, 10XBC, UMI, pCSl, probe BC, constant region, RHS, LHS and pRead 2S. In certain embodiments, the variant nucleotide(s) is present between the RHS and LHS in the barcoded target variant nucleic acid.
[0248] In certain embodiments, the method can further include contacting the individual cells and / or nuclei that have target nucleic acids hybridized to the mutation-specific probes with a second set of probes specific to mRNA transcripts within the cells (referred to herein as “transcriptome-specific probes”), e.g., as shown in FIG. 1. For example, but not by way of limitation, the sample can be contacted with the transcriptome-specific probes prior to
[0249] 516578835.1 42Attorney Ref. No. 00B206.1727
[0250] contacting the sample with the particles (e.g., beads coupled to barcode polynucleotides) and partitioning into compartments, as shown in FIG. 1. In certain embodiments, the transcriptome-specific probes can be commercially available transcriptome-specific probes, e.g., transcriptome-specific probes from lOx Genomics (e.g., from the GEM-X Flex Gene Expression system of lOx Genomics). In certain embodiments, the transcriptome-specific probes hybridize to the mRNAs of the cells and / or nuclei being analyzed in a method of the present disclosure for the analysis of the transcriptome. In certain embodiments, the transcriptome-specific probes can include a capture sequence comprising the same sequence as the capture sequence present in the mutation-specific probes. The use of the same capture sequence in the transcriptome-specific probes and the mutation-specific probes allows for the capture of both sets of probes by the barcode polynucleotides coupled to the particles, e.g., beads. As described herein for the mutation-specific probes, the UMI sequence, barcode and / or pReadlT sequence from the barcode polynucleotide coupled to the particle, e.g., bead, can be incorporated into the transcriptome-specific probes within the droplets to generate barcoded transcript-specific nucleic acids.
[0251] In certain embodiments, the method can further comprise combining the barcoded nucleic acids (e.g., the barcoded target variant nucleic acids and / or the barcoded transcriptspecific nucleic acids) from a plurality of the compartments, e.g., emulsion droplets, to generate pooled barcoded nucleic acids. For example, but not by way of limitation, the method includes combining the barcoded nucleic acids from a plurality of the compartments, e.g., emulsion droplets, to generate pooled barcoded nucleic acids. In certain embodiments, the barcoded nucleic acids (e.g., the barcoded target variant nucleic acids and / or the barcoded transcriptspecific nucleic acids) containing the UMI sequence, barcode and / or pReadlT sequence are removed from the compartment, e.g., emulsion droplet. For example, but not by way of limitation, the barcoded nucleic acids (e.g., the barcoded target variant nucleic acids and / or the barcoded transcript-specific nucleic acids) containing the UMI sequence, barcode and / or pReadlT sequence can be separated from the emulsion droplets by an unpacking process, where the barcoded nucleic acids (e.g., the barcoded target variant nucleic acids and / or the barcoded transcript-specific nucleic acids) present in the emulsion droplets are released. Any technique known in the art for breaking an emulsion can be used for the unpacking process. Non-limiting examples of techniques used for breaking an emulsion include acidification, centrifugation, filtration and the addition of salt. In certain embodiments, the unpacking process releases the barcoded nucleic acids from the emulsion droplets. In certain embodiments, the unpacked barcoded nucleic acids (e.g., the barcoded target variant nucleic
[0252] 516578835.1 43Attorney Ref. No. 00B206.1727
[0253] acids and / or the barcoded transcript-specific nucleic acids) can be cleaned up, e.g., using SPRIselect.
[0254] In certain embodiments, a subset of the released barcoded nucleic acids (e.g, the barcoded target variant nucleic acids and / or the barcoded transcript-specific nucleic acids) is pooled together. In certain embodiments, a subset of the barcoded nucleic acids (e.g, the barcoded target variant nucleic acids and / or the barcoded transcript-specific nucleic acids) released from the compartments, e.g., emulsion droplets, are pooled together. For example, but not by way of limitation, at least about 1%, at least about 2%, at least about 3%, at least about 4%, at least about 5%, at least about 6%, at least about 7%, at least about 8%, at least about 9%, at least about 10%, at least about 15%, at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, at least about 55%, at least about 60%, at least about 65%, at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98% or at least about 99% of the barcoded nucleic acids (e.g., the barcoded target variant nucleic acids and / or the barcoded transcript-specific nucleic acids) released from the compartments, e.g., emulsion droplets, are pooled together. In certain embodiments, at least about 1% of the barcoded nucleic acids released from the compartments, e.g., emulsion droplets, are pooled together. In certain embodiments, at least about 2% of the barcoded nucleic acids released from the compartments, e.g., emulsion droplets, are pooled together. In certain embodiments, at least about 10% of the barcoded nucleic acids released from the compartments, e.g., emulsion droplets, are pooled together. In certain embodiments, at least about 50% of the barcoded nucleic acids released from the compartments, e.g., emulsion droplets, are pooled together. In certain embodiments, about 1% to about 5% of the barcoded nucleic acids released from the compartments, e.g., emulsion droplets, are pooled together. In certain embodiments, about 1% to about 10% of barcoded nucleic acids released from the compartments, e.g., emulsion droplets, are pooled together. In certain embodiments, all the barcoded nucleic acids released from the compartments, e.g., emulsion droplets, are pooled together. In certain embodiments, all of the barcoded nucleic acids released from the compartments, e.g., emulsion droplets, are pooled together.
[0255] In certain embodiments, the method can further include preparing a library, e.g., a sequencing library, of the barcoded target nucleic acids (e.g., barcoded target variant nucleic acids) from the pooled barcoded nucleic acids. In certain embodiments, the method for preparing a library can include performing a pre-amplification process on the pooled barcoded
[0256] 516578835.1 44Attorney Ref. No. 00B206.1727
[0257] target nucleic acids (e.g., barcoded target variant nucleic acids) or a subset of the pooled barcoded target nucleic acids (e.g., barcoded target variant nucleic acids), e.g., as shown in FIGs. 3A-3B. For example, but not by way of limitation, the pre-amplification process can include amplifying the barcoded target nucleic acids (e.g., barcoded target variant nucleic acids) present in the pooled barcoded nucleic acids with a primer set that includes a primer specific for the barcoded target nucleic acids (e.g., barcoded target variant nucleic acids). In certain embodiments, the primer is complementary to the sequence of the mutation-specific probe present in the barcoded target nucleic acids that functions as a primer binding site. In certain embodiments, the spacer nucleotide sequence of the mutation-specific probe includes a nucleotide sequence that can function as a primer binding site. In certain embodiments, the nucleotide sequence that can function as a primer binding site comprises the nucleotide sequence GCAACGACTCCACACTCATA (SEQ ID NO: 1), as shown in Table 2. Any suitable nucleic acid amplification method known in the art can be used to amplify the barcoded target nucleic acids, and can include, without limitation, PCR, reverse transcriptase PCR, realtime PCR, RCA, 3 SR, NASBA, SDA, TMA, SPIA, HD A, LAMP, RPA, NEAR, NENNA and LCR. In certain embodiments, the pre-amplification method includes the PCR amplification of the barcoded target nucleic acids (e.g., barcoded target variant nucleic acids) using primers that are coupled to a label, e.g., biotin, for subsequent isolation of barcoded target nucleic acids (e.g., barcoded target variant nucleic acids) that are coupled to the label. In certain embodiments, the concentration of the primers specific for the barcoded target nucleic acids (e.g., barcoded target variant nucleic acids) is from about to about 1 pM to about 50 pM. In certain embodiments, the pre-amplification method can occur for a period of about 1 hour to about 24 hours, e.g., from about 1 hours to about 20 hours, from about 10 minutes to about 16 hours, from about 10 minutes to about 12 hours, from about 10 minutes to about 10 hours, from about 10 minutes to about 5 hours or from about 10 minutes to about 2 hours.
[0258] In certain embodiments, the method for preparing a library includes isolating the amplified barcoded target nucleic acids (e.g., barcoded target variant nucleic acids) from the amplified barcoded transcript-specific nucleic acids using the label coupled to the barcoded target nucleic acids (e.g., amplified barcoded target variant nucleic acids). Non-limiting examples of such labels include biotin or a magnetic bead (e.g., DYNABEADS™). For example, but not by way of limitation, enrichments for the amplified barcoded target nucleic acids can include using an agent that is specific to the label bound to the amplified barcoded target nucleic acids. In certain embodiments, enrichment can be performed by using avidin or
[0259] 516578835.1 45Attorney Ref. No. 00B206.1727
[0260] streptavidin if biotin is used as the label. Alternatively, a magnet can be used if a magnetic bead is used as the label and / or if streptavidin is coupled to a magnetic bead for binding biotinylated barcoded target nucleic acids. This process can be used to isolate the amplified barcoded target nucleic acids (e.g., amplified barcoded target variant nucleic acids) to prepare a library comprising the amplified barcoded target nucleic acids (e.g., amplified barcoded target variant nucleic acids). For example, but not by ways of limitation, the amplified barcoded target nucleic acids (e.g., barcoded target variant nucleic acids) can be biotinylated and isolated by using magnetic beads coupled to streptavidin.
[0261] In certain embodiments, the library of isolated amplified barcoded target nucleic acids (e.g., barcoded target variant nucleic acids) can be further generated by indexing the amplified barcoded target nucleic acids (e.g., amplified barcoded target variant nucleic acids), e.g., by performing Sample Index PCR (e.g., as shown in FIGs.3A-3B). For example, but not by way of limitation, P5, P7, i5 and i7 sample indexes, and Illumina TruSeq Read 1 sequence (Read IT) and Small RNA Read 2 (Read 2S) sequences are added via Sample Index PCR (e.g., as shown in FIGs. 3A-3B). In certain embodiments, the Sample Index PCR method can occur for a period of about 1 hour to about 24 hours, e.g., from about 1 hours to about 20 hours, from about 10 minutes to about 16 hours, from about 10 minutes to about 12 hours, from about 10 minutes to about 10 hours, from about 10 minutes to about 5 hours or from about 10 minutes to about 2 hours. In certain embodiments, the final library of the mutated nucleic acids contains the P5 and P7 priming sites used in Illumina sequencers (e.g., as shown in FIGs. 3A-3B), which can be used to further amplify the nucleic acids of the library, e.g., by an amplification method disclosed herein, e.g., PCR.
[0262] In certain embodiments, a method of the present disclosure can further include preparing a library of the barcoded transcript-specific nucleic acids from the pooled barcoded nucleic acids. For example, a library comprising the barcoded transcript-specific nucleic acids can be generated by performing a pre-amplification process, as described herein, using primers specific to the barcoded transcript-specific nucleic acids followed by the indexing the amplified barcoded transcript-specific nucleic acids, e.g., by performing Sample Index PCR. For example, but not by way of limitation, P5, P7, i5 and i7 sample indexes, and Illumina TruSeq Read 1 sequence (Read IT) and Small RNA Read 2 (Read 2S) sequences are added via Sample Index PCR. In certain embodiments, the Sample Index PCR method can occur for a period of about 1 hour to about 24 hours, e.g., from about 1 hours to about 20 hours, from about 10 minutes to about 16 hours, from about 10 minutes to about 12 hours, from about 10 minutes to about 10 hours, from about 10 minutes to about 5 hours or from about 10 minutes to about 2
[0263] 516578835.1 46Attorney Ref. No. 00B206.1727
[0264] hours. In certain embodiments, the final library of the amplified barcoded transcript-specific nucleic acids contains the P5 and P7 priming sites used in Illumina sequencers (e.g., as shown in FIGs. 3A-3B), which can be used to further amplify the nucleic acids of the library, e.g., by an amplification method disclosed herein, e.g, PCR.
[0265] In another aspect, the present disclosure further provides methods for sequencing a library generated according to the methods disclosed herein. In certain embodiments, the sequencing methods of the present disclosure comprise sequencing the library prepared from the variant target nucleic acids. In certain embodiments, the sequencing methods of the present disclosure comprise sequencing the library prepared from the transcript-specific nucleic acids. In certain embodiments, analysis of both the library prepared from the variant target nucleic acids and the library prepared from the transcript-specific nucleic acids allows for simultaneous analysis of the transcriptome and the target variant nucleic acids in a single sample, e.g, in a single cell of the sample as determined by the unique barcode incorporated in the amplified target variant nucleic acids and the amplified transcript-specific nucleic acids in the individual emulsion droplets.
[0266] In certain embodiments, a sequencing method of the present disclosure comprises sequencing all or a subset of the nucleic acids of a library. For example, but not by way of limitation, at least about 10%, at least about 15%, at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, at least about 55%, at least about 60%, at least about 65%, at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98% or at least about 99% of the nucleic acids included in the library can be sequenced. In certain embodiments, from about 10% to about 99% of the nucleic acids included in the library can be sequenced. In certain embodiments, from about 10% to about 95%, from about 10% to about 90%, from about 10% to about 80%, from about 10% to about 70%, from about 10% to about 60%, from about 10% to about 50%, from about 10% to about 40%, from about 10% to about 30%, from about 10% to about 20%, from about 20% to about 99%, from about 30% to about 99%, from about 40% to about 99%, from about 50% to about 99%, from about 60% to about 99%, from about 70% to about 99%, from about 80% to about 99%, from about 90% to about 99%, from about 20% to about 80% or from about 30% to about 50% of the nucleic acids of a library can be sequenced.
[0267] Appropriate sequencing methods can be used for sequencing the nucleic acids, e.g., the variant nucleic acids, of a library disclosed herein. In certain embodiments, the nucleic acids
[0268] 516578835.1 47Attorney Ref. No. 00B206.1727
[0269] can be sequenced by a high throughput sequencing method. In certain embodiments, the nucleic acids can be sequenced by next-generation sequencing (NGS). For example, but not by way of limitation, sequencing can be performed using the Illumina NGS platform. In certain embodiments, the nucleic acids can be sequenced by a pyrosequencing method. In certain embodiments, the nucleic acids can be sequenced by Sanger sequencing. In certain embodiments, the nucleic acids can be sequenced using nanopore-based sequencing. In certain embodiments, the sequence reads obtained using the methods of the present disclosure can be attributed to specific cells based upon the unique sequences included in the barcode polynucleotide coupled to the particles.
[0270] V. KITS
[0271] The present disclosure provides kits for performing the methods of the present disclosure. For example, but not by way of limitation, the present disclosure provides kits containing materials and / or reagents for performing a method for detecting variant nucleic acids in a plurality of single cells.
[0272] In certain embodiments, a kit of the present disclosure can comprise reagents for preparing sample. For example, but not by way of limitation, a kit of the present disclosure can comprise reagents for performing a fixation process and / or a permeabilization process.
[0273] In certain embodiments, the present disclosure provides kits containing materials for performing a gap filling process. For example, but not by way of limitation, a kit of the present disclosure can include one or more mutation-specific probes, e.g., to detect mutations disclosed herein (e.g., in Table 1), reversible terminator nucleotides and / or a ligase. For example, but not by way of limitation, a kit of the present disclosure can include a padlock mutation-specific probe comprising (i) a left homology site, (ii) pR2S, (iii) a spacer sequence, (iv) a capture sequence, (v) a probe barcode sequence, (vi) a constant region and (vii) a right homology site, as shown in FIG. 3A. In certain embodiments, a kit of the present disclosure can include a padlock mutation-specific probe of the present disclosure comprising the following sequences in the 3’ to 5’ orientation: (i) a left homology site, (ii) a spacer sequence, (iii) a capture sequence, (iv) a probe barcode sequence, (v) a constant region and (vi) a right homology site. In certain embodiments, a kit of the present disclosure can include a padlock mutation-specific probe of the present disclosure comprising the following sequences in the 3’ to 5’ orientation: (i) a left homology site, (ii) pR2S, (iii) a spacer sequence, (iv) a capture sequence, (v) a probe barcode sequence, (vi) a constant region and (vii) a right homology site. In certain embodiments, a kit of the present disclosure can include a pair of linear mutation-specific
[0274] 516578835.1 48Attorney Ref. No. 00B206.1727
[0275] probes comprising a first linear probe and a second linear probe, where the first linear probe comprises (i) a left homology site, (ii) pR2S and (iii) a spacer sequence and the second linear probe comprises (i) a capture sequence (also referred to herein as “pCSl”), (ii) a probe barcode sequence, (iii) a constant region and (vii) a right homology site, as shown in FIG. 3B. In certain embodiments, a kit of the present disclosure can include a pair of linear mutationspecific probes comprising a first linear probe and a second linear probe, where the first linear probe comprises the following sequences in the 3’ to 5’ orientation: (i) a left homology site and (ii) a spacer sequence and the second linear probe of the present disclosure comprises the following sequences in the 3’ to 5’ orientation: (i) a capture sequence (also referred to herein as “pCSl”), (ii) a probe barcode sequence, (iii) a constant region and (vii) a right homology site. In certain embodiments, a kit of the present disclosure can include a pair of linear mutation-specific probes comprising a first linear probe and a second linear probe, where the first linear probe comprises the following sequences in the 3’ to 5’ orientation: (i) a left homology site, (ii) pR2S and (iii) a spacer sequence and the second linear probe of the present disclosure comprises the following sequences in the 3’ to 5’ orientation: (i) a capture sequence (also referred to herein as “pCSl”), (ii) a probe barcode sequence, (iii) a constant region and (vii) a right homology site.
[0276] In certain embodiments, the present disclosure provides kits containing materials for performing a method for generating a sequencing library comprising nucleic acids from a plurality of single cells. In certain embodiments, the present disclosure provides kits containing materials for sequencing a library comprising nucleic acids from a plurality of single cells.
[0277] In certain embodiments, a kit of the present disclosure can further include reagents for generating emulsion droplets. For example, but not by way of limitation, a kit can include one or more aqueous and / or non-aqueous fluids. In certain embodiments, a kit can include materials for performing an emulsion droplet generating technique, e.g., a pipettor and / or vortexer. Alternatively or additionally, a kit of the present disclosure can include an emulsion generating device, e.g., a microfluidic device.
[0278] In certain embodiments, a kit of the present disclosure can further include reagents for performing an amplification reaction. In certain embodiments, the reagents can include one more of the following: polymerases, reverse transcriptases, nucleoside triphosphates or NTP analogues, primers, cofactors, ligation reaction reagents, endonucleases, lysis reagents, dyes, markers and labels.
[0279] In certain embodiments, a kit of the present disclosure can further comprise reagents for performing a reverse transcription reaction. In certain embodiments, a kit of the present
[0280] 516578835.1 49Attorney Ref. No. 00B206.1727
[0281] disclosure can further comprise reagents for performing an amplification reaction. For example, but not by way of limitation, a kit of the present disclosure can comprise reagents comprising one more of the following: polymerases (e.g., phi29 polymerase and / or Taq polymerase), RNA polymerases (e.g., T7 RNA polymerase), reverse transcriptases, nucleoside triphosphates or NTP analogues, primers, padlock probes, cofactors, ligation reaction reagents, endonucleases, lysis reagents, dyes, markers, RNase inhibitors and labels.
[0282] In certain embodiments, the kit further includes a package insert that provides instructions for using the components provided in the kit. For example, a kit of the present disclosure can include a package insert that provides instructions for detecting variant nucleic acids in a sample.
[0283] In certain embodiments, the kit can include other materials desirable from a commercial and user standpoint, including other buffers and diluents. In certain embodiments, the kit can include materials or reagents for dissociating samples into single cells or for isolating nuclei from single cells.
[0284] In certain embodiments, the components of the kit are provided in predetermined ratios, with the relative amounts of the various reagents suitably varied to obtain the desired sensitivity and throughput of the disclosed methods.
[0285] VI. SYSTEMS
[0286] The present disclosure provides systems for performing the methods of the present disclosure. For example, but not by way of limitation, the present disclosure provides systems containing materials for performing a method for detecting variant nucleic acids in a plurality of single cells. For example, but not by way of limitation, the present disclosure provides systems that include materials or reagents (e.g., in one or more reservoirs or containers) for performing a method for detecting a variant nucleic acid in a sample. In certain embodiments, the system is an automated system. In certain embodiments, the automated system includes one or more automated pipettes for dispensing materials or reagents onto a sample. In certain embodiments, a system of the present disclosure can include an emulsion generating device, e.g., a microfluidic device.
[0287] In certain embodiments, a system of the present disclosure can further comprise reagents for preparing a sample (e.g., in one or more reservoirs or containers). For example, but not by way of limitation, a system of the present disclosure can comprise reagents for performing a fixation process and / or a permeabilization process. Non-limiting examples of
[0288] 516578835.1 50Attorney Ref. No. 00B206.1727
[0289] such reagents comprise a fixative (e.g., an aldehyde) and / or a permeabilizing reagent (e.g., an alcohol).
[0290] In certain embodiments, a system of the present disclosure can further comprise reagents for performing a gap filling process (e.g., in one or more reservoirs or containers). For example, but not by way of limitation, a system of the present disclosure can include one or more mutation-specific probes, e.g., to detect mutations disclosed herein (e.g., in Table 1), reversible terminator nucleotides and / or a ligase (e.g., in one or more reservoirs or containers). For example, but not by way of limitation, a system of the present disclosure can include a padlock mutation-specific probe comprising (i) a left homology site, (ii) pR2S, (iii) a spacer sequence, (iv) a capture sequence, (v) a probe barcode sequence, (vi) a constant region and (vii) a right homology site, as shown in FIG.3A (e.g., in one or more reservoirs or containers). In certain embodiments, a system of the present disclosure can include a padlock mutationspecific probe of the present disclosure comprising the following sequences in the 3’ to 5’ orientation: (i) a left homology site, (ii) a spacer sequence, (iii) a capture sequence, (iv) a probe barcode sequence, (v) a constant region and (vi) a right homology site (e.g., in one or more reservoirs or containers). In certain embodiments, a system of the present disclosure can include a padlock mutation-specific probe of the present disclosure comprising the following sequences in the 3’ to 5’ orientation: (i) a left homology site, (ii) pR2S, (iii) a spacer sequence, (iv) a capture sequence, (v) a probe barcode sequence, (vi) a constant region and (vii) a right homology site (e.g., in one or more reservoirs or containers). In certain embodiments, a system of the present disclosure can include a pair of linear mutation-specific probes comprising a first linear probe and a second linear probe, where the first linear probe comprises (i) a left homology site, (ii) pR2S and (iii) a spacer sequence and the second linear probe comprises (i) a capture sequence (also referred to herein as “pCSl”), (ii) a probe barcode sequence, (iii) a constant region and (vii) a right homology site, as shown in FIG. 3B (e.g., in one or more reservoirs or containers). In certain embodiments, a system of the present disclosure can include a pair of linear mutation-specific probes comprising a first linear probe and a second linear probe, where the first linear probe comprises the following sequences in the 3’ to 5’ orientation: (i) a left homology site and (iii) a spacer sequence and the second linear probe of the present disclosure comprises the following sequences in the 3 ’ to 5 ’ orientation: (i) a capture sequence (also referred to as “pCSl”), (ii) a probe barcode sequence, (iii) a constant region and (vii) a right homology site (e.g., in one or more reservoirs or containers). In certain embodiments, a system of the present disclosure can include a pair of linear mutation-specific probes comprising a first linear probe and a second linear probe, where the first linear probe
[0291] 516578835.1 51Attorney Ref. No. 00B206.1727
[0292] comprises the following sequences in the 3’ to 5’ orientation: (i) a left homology site, (ii) pR2S and (iii) a spacer sequence and the second linear probe of the present disclosure comprises the following sequences in the 3’ to 5’ orientation: (i) a capture sequence (also referred to as “pCSl”), (ii) a probe barcode sequence, (iii) a constant region and (vii) a right homology site (e.g., in one or more reservoirs or containers).
[0293] In certain embodiments, a system of the present disclosure can further comprise reagents (e.g., in one or more reservoirs or containers) for performing an amplification reaction. In certain embodiments, the reagents can include one more of the following: polymerases, reverse transcriptases, nucleoside triphosphates or NTP analogues, primers, cofactors, ligation reaction reagents, endonucleases, lysis reagents, dyes, markers and labels.
[0294] In certain embodiments, a system of the present disclosure can further comprise reagents (e.g., in one or more reservoirs or containers) for performing a reverse transcription reaction. In certain embodiments, a system of the present disclosure can further comprise reagents for performing an amplification reaction. For example, but not by way of limitation, a system of the present disclosure can comprise reagents comprising one more of the following: polymerases (e.g., phi29 polymerase and / or Taq polymerase), RNA polymerases (e.g., T7 RNA polymerase), reverse transcriptases, nucleoside triphosphates or NTP analogues, primers, padlock probes, cofactors, ligation reaction reagents, endonucleases, lysis reagents, dyes, markers, RNase inhibitors and labels.
[0295] In certain embodiments, the components of the system are provided in predetermined ratios, with the relative amounts of the various reagents suitably varied to obtain the desired sensitivity and throughput of the disclosed methods.
[0296] VI. EXEMPLARY EMBODIMENTS
[0297] A. The present disclosure provides a method for generating a library comprising a variant of a target nucleic acid or for identifying a variant of a target nucleic acid, comprising:
[0298] (a) providing a plurality of cells or nuclei;
[0299] (b) contacting the plurality of cells or nuclei with at least one mutation-specific probe that hybridizes to a target nucleic acid, wherein the mutation-specific probe comprises a gap of at least one nucleotide and / or generates a gap of at least one nucleotide upon hybridization to the target nucleic acid; and
[0300] (c) performing a gap filling process, wherein the gap filling process comprises:
[0301] (i) contacting the mutation-specific probe hybridized to the target nucleic acid with reversible terminator nucleotides to incorporate a reversible terminator nucleotide
[0302] 516578835.1 52Attorney Ref. No. 00B206.1727
[0303] comprising a blocking group into the gap of the mutation-specific probe or the gap generated by hybridization of the mutation-specific probe to the target nucleic acid;
[0304] (ii) removing the blocking group from the reversible terminator nucleotide incorporated into the mutation-specific probe; and
[0305] (iii) ligating the mutation-specific probe to generate a gap filled mutationspecific probe.
[0306] Al. The method of A further comprising generating a target nucleic acid-specific library comprising the sequence of the gap filled mutation specific probe or the sequence complementary to the gap filled mutation specific probe.
[0307] B. The present disclosure provides a method for generating a library comprising a variant of a target nucleic acid, comprising:
[0308] (a) providing a plurality of cells or nuclei;
[0309] (b) contacting the plurality of cells or nuclei with at least one mutation-specific probe that hybridizes to a target nucleic acid, wherein the mutation-specific probe comprises a gap of at least one nucleotide and / or generates a gap of at least one nucleotide upon hybridization to the target nucleic acid;
[0310] (c) performing a gap filling process, wherein the gap filling process comprises:
[0311] (i) contacting the mutation-specific probe hybridized to the target nucleic acid with reversible terminator nucleotides to incorporate a reversible terminator nucleotide comprising a blocking group into the gap of the mutation-specific probe or the gap generated by hybridization of the mutation-specific probe to the target nucleic acid;
[0312] (ii) removing the blocking group from the reversible terminator nucleotide incorporated into the mutation-specific probe; and
[0313] (iii) ligating the mutation-specific probe to generate a gap filled mutationspecific probe;
[0314] (d) contacting the cells or nuclei comprising the gap filled mutation-specific probes with a plurality of particles, wherein each of the particles is coupled to a polynucleotide comprising a barcode;
[0315] (e) partitioning individual particles of the plurality of particles and the cells or nuclei comprising the gap filled mutation-specific probes into compartments;
[0316] (f) incorporating the barcode of the polynucleotide into the gap filled mutationspecific probes to generate barcoded target nucleic acids;
[0317] (g) combining all or a subset of the barcoded target nucleic acids to generate pooled barcoded nucleic acids; and
[0318] 516578835.1 53Attorney Ref. No. 00B206.1727
[0319] (i) generating a target nucleic acid-specific library comprising the barcoded transcript-specific nucleic acids from the pooled barcoded nucleic acids.
[0320] C. The present disclosure provides a method for generating a library comprising a variant of a target nucleic acid, comprising:
[0321] (a) providing a plurality of cells or nuclei;
[0322] (b) contacting the plurality of cells or nuclei with at least one mutation-specific probe that hybridizes to a target nucleic acid, wherein the mutation-specific probe comprises a gap of at least one nucleotide and / or generates a gap of at least one nucleotide upon hybridization to the target nucleic acid;
[0323] (c) performing a gap filling process, wherein the gap filling process comprises:
[0324] (i) contacting the mutation-specific probe hybridized to the target nucleic acid with reversible terminator nucleotides to incorporate a reversible terminator nucleotide comprising a blocking group into the gap of the mutation-specific probe or the gap generated by hybridization of the mutation-specific probe to the target nucleic acid;
[0325] (ii) removing the blocking group from the reversible terminator nucleotide incorporated into the mutation-specific probe; and
[0326] (iii) ligating the mutation-specific probe to generate a gap filled mutationspecific probe;
[0327] (d) contacting the cells or nuclei comprising the gap filled mutation-specific probes with a plurality of transcriptome-specific probes;
[0328] (e) contacting the cells or nuclei comprising the gap filled mutation-specific probes and the transcriptome-specific probes with a plurality of particles, wherein each of the particles is coupled to a polynucleotide comprising a barcode;
[0329] (f) partitioning individual particles of the plurality of particles and the cells or nuclei comprising the gap filled mutation-specific probes and the transcriptome-specific probes into compartments;
[0330] (g) incorporating the barcode of the polynucleotide into the gap filled mutationspecific probes to generate barcoded target nucleic acids and incorporating the barcode of the polynucleotide into the transcriptome-specific probes to generate barcoded transcript-specific nucleic acids in the compartments, wherein the barcode of the barcoded target nucleic acids and the barcode of the barcoded transcript-specific nucleic acids present in a single compartment comprise the same nucleotide sequence;
[0331] (h) combining all or a subset of the barcoded target nucleic acids and the barcoded transcript-specific nucleic acids from the compartments to generate pooled barcoded nucleic
[0332] 516578835.1 54Attorney Ref. No. 00B206.1727
[0333] acids; and
[0334] (i) generating a target nucleic acid-specific library comprising the barcoded transcript-specific nucleic acids from the pooled barcoded nucleic acids.
[0335] Cl. The method of B or C further comprising sequencing all or a subset of the barcoded target nucleic acids in the target nucleic acid-specific library to identify one or more variants of the target nucleic acids.
[0336] C2. The method of C or Cl further comprising sequencing all or a subset of the barcoded transcript-specific nucleic acids in the target nucleic acid-specific library.
[0337] C3. The method of C further comprising generating a transcript-specific library comprising the barcoded transcript-specific nucleic acids from the pooled barcoded nucleic acids.
[0338] C4. The method of C3 further comprising further comprising sequencing all or a subset of the barcoded transcript-specific nucleic acids in the transcript-specific library.
[0339] D. The present disclosure provides a method for identifying a variant of a target nucleic acid, comprising:
[0340] (a) providing a plurality of cells or nuclei;
[0341] (b) contacting the plurality of cells or nuclei with at least one mutation-specific probe that hybridizes to a target nucleic acid, wherein the mutation-specific probe comprises a gap of at least one nucleotide and / or generates a gap of at least one nucleotide upon hybridization to the target nucleic acid;
[0342] (c) performing a gap filling process, wherein the gap filling process comprises:
[0343] (i) contacting the mutation-specific probe hybridized to the target nucleic acid with reversible terminator nucleotides to incorporate a reversible terminator nucleotide comprising a blocking group into the gap of the mutation-specific probe or the gap generated by hybridization of the mutation-specific probe to the target nucleic acid;
[0344] (ii) removing the blocking group from the reversible terminator nucleotide incorporated into the mutation-specific probe; and
[0345] (iii) ligating the mutation-specific probe to generate a gap filled mutationspecific probe;
[0346] (d) contacting the cells or nuclei comprising the gap filled mutation-specific probes, wherein each of the particles is coupled to a polynucleotide comprising a barcode;
[0347] (e) partitioning individual particles of the plurality of particles and the cells or nuclei comprising the gap filled mutation-specific probes into compartments;
[0348] (f) incorporating the barcode of the polynucleotide into the gap filled mutationspecific probes to generate barcoded target nucleic acids;
[0349] 516578835.1 55Attorney Ref. No. 00B206.1727
[0350] (g) combining all or a subset of the barcoded target nucleic acids to generate pooled barcoded nucleic acids;
[0351] (i) generating a target nucleic acid-specific library comprising the barcoded transcript-specific nucleic acids from the pooled barcoded nucleic acids; and
[0352] (j) sequencing all or a subset of the barcoded target nucleic acids in the library to identify one or more variants of the target nucleic acids.
[0353] E. The present disclosure provides a method for identifying a variant of a target nucleic acid, comprising:
[0354] (a) providing a plurality of cells or nuclei;
[0355] (b) contacting the plurality of cells or nuclei with at least one mutation-specific probe that hybridizes to a target nucleic acid, wherein the mutation-specific probe comprises a gap of at least one nucleotide and / or generates a gap of at least one nucleotide upon hybridization to the target nucleic acid;
[0356] (c) performing a gap filling process, wherein the gap filling process comprises:
[0357] (i) contacting the mutation-specific probe hybridized to the target nucleic acid with reversible terminator nucleotides to incorporate a reversible terminator nucleotide comprising a blocking group into the gap of the mutation-specific probe or the gap generated by hybridization of the mutation-specific probe to the target nucleic acid;
[0358] (ii) removing the blocking group from the reversible terminator nucleotide incorporated into the mutation-specific probe; and
[0359] (iii) ligating the mutation-specific probe to generate a gap filled mutationspecific probe;
[0360] (d) contacting the cells or nucleic comprising the gap filled mutation-specific probes with a plurality of transcriptome-specific probes;
[0361] (e) contacting the cells or nuclei comprising the gap filled mutation-specific probes and the transcriptome-specific probes with a plurality of particles, wherein each of the particles is coupled to a polynucleotide comprising a barcode;
[0362] (f) partitioning individual particles of the plurality of particles and the cells or nuclei comprising the gap filled mutation-specific probes and the transcriptome-specific probes into compartments;
[0363] (g) incorporating the barcode of the polynucleotide into the gap filled mutationspecific probes to generate barcoded target nucleic acids and incorporating the barcode of the polynucleotide into the transcriptome-specific probes to generate barcoded transcript-specific nucleic acids in the compartments, wherein the barcode of the barcoded target nucleic acids
[0364] 516578835.1 56Attorney Ref. No. 00B206.1727
[0365] and the barcode of the barcoded transcript-specific nucleic acids present in a single compartment comprise the same nucleotide sequence;
[0366] (h) combining all or a subset of the barcoded target nucleic acids and the barcoded transcript-specific nucleic acids from the compartments to generate pooled barcoded nucleic acids;
[0367] (i) generating a target nucleic acid-specific library comprising the barcoded target nucleic acids from the pooled barcoded nucleic acids;
[0368] (j) generating a transcript-specific library comprising the barcoded transcriptspecific nucleic acids from the pooled barcoded nucleic acids; and
[0369] (k) sequencing all or a subset of the barcoded target nucleic acids in the library to identify one or more variants of the target nucleic acids.
[0370] El. The method of E further comprising sequencing all or a subset of the barcoded transcript-specific nucleic acids in the library to identify transcript-specific nucleic acids. E2. The method of E or El further comprising comparing the barcoded target nucleic acids to the transcript-specific nucleic acids in a single cell.
[0371] E3. The method of any one of B-E2, wherein the generation of a library comprising the barcoded target nucleic acids comprises (i) amplifying the barcoded target nucleic acids by contacting the pool of barcoded nucleic acids with one or more primers coupled to a label to generate amplified barcoded target nucleic acids coupled to the label, wherein the one or more primers specifically hybridize to the barcoded target nucleic acids and (ii) isolating the amplified target nucleic acids coupled to the label to generate the library.
[0372] E4. The method of E3, wherein the label comprises biotin.
[0373] E5. The method of E3 or E4, wherein isolating the amplified target nucleic acids coupled to the label comprises contacting the sample with an agent that binds to the label.
[0374] E6. The method of E5, wherein the agent comprises streptavidin.
[0375] E7. The method of any one of A-E6, wherein the gap of at least one nucleotide corresponds to at least one nucleotide that is variant in the target nucleic acid compared to a reference sequence.
[0376] E8. The method of any one of A-E7, wherein the mutation-specific probes are padlock probes.
[0377] E9. The method of E8, wherein the padlock probes comprise a first homology region that is complementary to a first sequence of the target nucleic acid and a second homology region that is complementary to a second sequence of the target nucleic acid, and wherein the gap of at least one nucleotide is located between the first homology region and the second homology
[0378] 516578835.1 57Attorney Ref. No. 00B206.1727
[0379] region.
[0380] E10. The method of any one of A-E7, wherein the mutation-specific probes comprise a pair of linear probes.
[0381] Ell. The method of E10, wherein one probe of the pair of linear probes comprises a first homology region that is complementary to a first sequence of the target nucleic acid and the second probe of the pair of linear probes comprises a second homology region that is complementary to a second sequence of the target nucleic acid, and wherein the gap of at least one nucleotide is located between the first homology region and the second homology region. E12. The method of any one of A-El 1, wherein the gap of at least one nucleotide corresponds to the nucleotides that are variant in the target nucleic acid.
[0382] E13. The method of any one of A-E12, wherein the mutation-specific probes and / or the transcriptome-specific probes comprise one or more of the following: (a) constant region sequence, (b) a spacer sequence and (c) a capture sequence.
[0383] E14. The method of E13, wherein the mutation-specific probes comprise (a) constant region sequence.
[0384] E15. The method of E13 or E14, wherein the mutation-specific probes comprise (b) a spacer sequence.
[0385] E16. The method of any one of E14-E15, wherein the mutation-specific probes comprise (c) a capture sequence.
[0386] E17. The method of E13, wherein the mutation-specific probes comprise (a) constant region sequence, (b) a spacer sequence and (c) a capture sequence.
[0387] E18. The method of any one of E13-E17, wherein the constant region sequence, the spacer sequence or the capture sequence comprises a primer binding nucleotide sequence for use in amplifying the barcoded target nucleic acids.
[0388] E19. The method of any one of E13-E18, wherein the polynucleotides comprising the barcode further comprises a sequence that hybridizes to the capture sequence of the mutationspecific probes and / or the transcriptome-specific probes.
[0389] E20. The method of any one of A-E19, wherein the plurality of cells or nuclei are treated with a fixative prior to step (a).
[0390] E21. The method of any one of A-E20, wherein the plurality of cells is permeabilized or lysed prior to step (a).
[0391] E22. The method of E21, wherein the plurality of cells is permeabilized prior to step (a). E23. The method of E21, wherein the plurality of cells is lysed prior to step (a).
[0392] E24. The method of any one of A-E12, wherein the compartments are emulsion droplets.
[0393] 516578835.1 58Attorney Ref. No. 00B206.1727
[0394] E25. The method of E24, wherein the emulsion droplets are generated in an emulsion droplet generating device or generated using an emulsion droplet generating technique.
[0395] E26. The method of any one of A-E25, wherein the target nucleic acid comprises RNA. E27. The method of any one of A-E26, wherein the target nucleic acid comprises DNA. E28. The method of any one of A-E27, wherein the plurality of cells comprises cancer cells. E29. The method of any one of A-E28 for use in identifying a variant of a target nucleic acid in a sample from a subject.
[0396] E30. The method of any one of A-E29 for use in diagnosing a disease in a subject.
[0397] E31. The method of any one of A-E29 for use in diagnosing cancer in a subject.
[0398] F. The present disclosure provides a kit for performing the method of any one of A-E31. F 1. The kit of F comprising a mutation-specific probe comprising:
[0399] (i) a first homology region that is complementary to a first sequence of the target nucleic acid;
[0400] (ii) a second homology region that is complementary to a second sequence of the target nucleic acid; and
[0401] (iii) a gap of at least one nucleotide is located between the first homology region and the second homology region (e.g., when hybridized to the target nucleic acid), wherein the gap of at least one nucleotide corresponds to a nucleotide that is variant in a target nucleic acid.
[0402] F2. The kit of Fl, wherein the mutation-specific probe further comprises one or more of the following: (a) constant region sequence, (b) a spacer sequence and (c) a capture sequence. F3. The kit of F 1 or F2, wherein the mutation-specific probe further comprises (a) constant region sequence.
[0403] F4. The kit of any one of F1-F3, wherein the mutation-specific probe further comprises (b) a spacer sequence.
[0404] F5. The kit of any one of F1-F4, wherein the mutation-specific probe further comprises (c) a capture sequence.
[0405] F6. The kit of any one of F1-F5, wherein the mutation-specific probe further comprises (a) constant region sequence, (b) a spacer sequence and (c) a capture sequence.
[0406] F7. The kit of any one of F2-F6, wherein the constant region sequence, the spacer sequence or the capture sequence comprises a primer binding nucleotide sequence for use in amplifying the barcoded target nucleic acids.
[0407] G. The present disclosure provides a system for performing the method of any one of A- E31.
[0408] 516578835.1 59Attorney Ref. No. 00B206.1727
[0409] G1. The system of G comprising a mutation-specific probe comprising:
[0410] (i) a first homology region that is complementary to a first sequence of the target nucleic acid;
[0411] (ii) a second homology region that is complementary to a second sequence of the target nucleic acid; and
[0412] (iii) a gap of at least one nucleotide is located between the first homology region and the second homology region (e.g., when hybridized to the target nucleic acid), wherein the gap of at least one nucleotide corresponds to a nucleotide that is variant in a target nucleic acid.
[0413] G2. The system of Gl, wherein the mutation-specific probe further comprises one or more of the following: (a) constant region sequence, (b) a spacer sequence and (c) a capture sequence.
[0414] G3. The system of Gl or G2, wherein the mutation-specific probe further comprises (a) constant region sequence.
[0415] G4. The system of any one of G1-G3, wherein the mutation-specific probe further comprises (b) a spacer sequence.
[0416] G5. The system of any one of G1-G4, wherein the mutation-specific probe further comprises (c) a capture sequence.
[0417] G6. The system of any one of G1-G5, wherein the mutation-specific probe further comprises (a) constant region sequence, (b) a spacer sequence and (c) a capture sequence. G7. The system of any one of G2-G6, wherein the constant region sequence, the spacer sequence or the capture sequence comprises a primer binding nucleotide sequence for use in amplifying the barcoded target nucleic acids.
[0418] H. The present disclosure provides a mutation-specific probe (e.g., for use in the methods described herein) comprising:
[0419] (i) a left homology site comprising a sequence that is complementary to a first sequence of a target nucleic acid;
[0420] (ii) a spacer sequence;
[0421] (iii) a capture sequence;
[0422] (iv) a probe barcode sequence;
[0423] (v) a constant region; and
[0424] (vi) a right homology site comprising a sequence that is complementary to a sequence of the target nucleic acid.
[0425] Hl . The mutation-specific probe of H, wherein the mutation-specific probe generates a gap
[0426] 516578835.1 60Attorney Ref. No. 00B206.1727
[0427] upon binding of the left homology site and the right homology site to the target nucleic acid, and wherein the gap corresponds to the variant sequence in the target nucleic acid.
[0428] 1. The present disclosure provides a mutation-specific probe pair comprising:
[0429] (i) a first linear probe comprising:
[0430] a. a left homology site comprising a sequence that is complementary to a first sequence of a target nucleic acid; and
[0431] b. a spacer sequence;
[0432] (ii) a second linear probe comprising:
[0433] a. a capture sequence;
[0434] b. a probe barcode sequence;
[0435] c. a constant region; and
[0436] d. a right homology site comprising a sequence that is complementary to a sequence of the target nucleic acid,
[0437] wherein the mutation-specific probe pair generates a gap upon binding of the left homology site and the right homology site to the target nucleic acid, and wherein the gap corresponds to or includes the variant sequence in the target nucleic acid.
[0438] 11. The mutation-specific probe of H, Hl or I, wherein the spacer sequence comprises a nucleotide sequence that has about 75%, about 80%, about 85%, about 90%, about 95%, about 96%, about 97%, about 98%, about 99% or about 100% homology to SEQ ID NO: 1.
[0439] 12. The mutation-specific probe of any one of H-Hl and I-Il, wherein the constant region comprises a nucleotide sequence that has about 75%, about 80%, about 85%, about 90%, about 95%, about 96%, about 97%, about 98%, about 99% or about 100% homology to SEQ ID NO: 2.
[0440] 13. The mutation-specific probe of any one of H-Hl and I-I2, wherein the capture sequence comprises a nucleotide sequence that has about 75%, about 80%, about 85%, about 90%, about 95%, about 96%, about 97%, about 98%, about 99% or about 100% homology to SEQ ID NO: 3.
[0441] J. The present disclosure further provides a composition comprising the mutationspecific probe of any one of H-Hl and I-I3.
[0442] EXAMPLES
[0443] The presently disclosed subject matter will be better understood by reference to the following example, which is provided as exemplary of the presently disclosed subject matter, and not by way of limitation.
[0444] 516578835.1 61Attorney Ref. No. 00B206.1727
[0445] Example 1. Method for detecting variant nucleic acids.
[0446] This example provides an exemplary method for the detection of nucleic acid variants in a sample. In this method, customized probes specific to preselected mutations, e.g., KRAS G12C, were designed that can be used together with commercially available probes for assessing levels of gene expression.
[0447] An exemplary method of the present disclosure as shown in FIG. 1 includes the following steps. The presently disclosed method includes thawing 2 million 4% PFA fixed cells or nuclei. Fresh cells or tissue can also be used in the disclosed method, where the method include performing a fixation process, e.g., in 4% PFA. Following the thawing of the fixed cells or nuclei or the fixing of the cells or nuclei from a sample, the cells or nuclei can undergo permeabilization, e.g., in the presence of 100% methanol.
[0448] The method further includes the hybridization and ligation of mutation-specific probes to the nucleic acids of interest. Padlock probes specific to somatic mutations of interest were prepared and their performance was compared in several human cell lines of known mutation status including H358 (non-small cell lung cancer (NSCLC) cell line), PC9 (NSCLC cell line) and K562 (chronic myeloid leukemia (CML) cell line). Exemplary mutation-specific probes are shown in FIG. 2 and FIGs. 3A-3B. The hybridization and ligation of the mutation probes included adding Yeast tRNA and RNase inhibitor to a hybridization buffer (Hyb Buff) stock while keeping it on ice following by heating the mutation-specific probes (e.g., mutationspecific padlock probes or mutation-specific linear probes) at 95°C for 3 min and then placed on ice. The hybridization reaction was then prepared and hybridization of the mutation-specific probes to the target nucleic acids was performed overnight. The following day, an RNase inhibitor was added to PBST to generate a Nuclei Washing Buffer (NWB) that was kept on ice. The cells or nucleic were then washed twice with 1000 pL NWB. The reverse transcription (RT) mix, which included reversible terminator nucleotides, was prepared and the cells or nucleic were resuspended in the RT reaction mix and RT was performed at 42°C for 60 min.
[0449] 1,000 pL NWB was added followed by centrifugation for 5 min. The cleavage reaction (i.e., the reaction to remove the blocking groups from the reversible terminator nucleotides) was run in 100 pL each followed by the addition of 1,000 pL NWB and centrifugation for 5 min. 500 pL Ligation Mix (LM) was prepared and the nuclei or cells were resuspended with 100 pL LM
[0450] 516578835.1 62Attorney Ref. No. 00B206.1727
[0451] and incubated at 40°C for 2 hours followed by a hold at 4°C overnight. 1000 pL NWB was added to the sample followed by centrifugation for 5 minutes.
[0452] The method then included contacting the samples with the standard lOx Genomics Flex RNA probes (fortranscriptome analysis), performing the standard lOx Genomics RNA probes hybridization and the standard lOx Genomics Flex chip for droplet Generation, which includes collecting the emulsions and clean up as standard protocol to incorporate barcodes into the mutation-specific probes and the lOx Genomics Flex RNA probes.
[0453] The method further included the construction of libraries by running a pre-amplification process with biotin-labeled primers designed for the mutation-specific probes to generate mutation specific-amplicons coupled to biotin. The biotin-labeled primers were complementary to the region of the mutation-specific probe that can function as a primer binding site (referred to as a “spacer sequence” in Table 2). Each mutation-specific probe can include the same sequence to allow for bulk amplification and generation of mutation specificamplicons coupled to biotin. The method included isolation of the mutation-specific amplicons by streptavidin beads. The final mutation-specific library was generated by performing by PCR with standard Illumina adaptors from the beads. A separate transcriptome library was constructed by using the supernatant from the isolation step that includes the transcriptomespecific amplicons. The libraries were then sequenced using standard settings for both the mutation-specific libraries and transcriptome-specific libraries.
[0454] Analysis and integration were then performed by running the standard analysis for transcriptome results followed by obtaining gene annotations. The mutation-specific analysis was performed to obtain the genotype along with the single-cell barcodes. The genotype annotations can be combined with the gene annotations based on shared barcodes.
[0455] Initial experiments were performed using direct ligation at 25°C and 40°C using probes targeting the mutations shown in Table 1 and having the structure shown in FIGs. 3A-3B. Table 2 provides the nucleotide sequences that are incorporated into the mutation-specific probes. As shown in FIG. 4, many false positive detections were observed. This is due to the mismatch tolerant nature of the ligase used in the Flex Fixed RNA Profiling (FRP) pipeline of lOx Genomics. Further experiments were performed to compare the use of direct ligation with linear mutation-specific probes or padlock mutation-specific probes. As shown in FIG. 6, padlock probes provided better accuracy compared to linear probes.
[0456] 516578835.1 63Attorney Ref No. 00B206.1727
[0457] Table 1
[0458] Gene Mutation Position On Nci-H358 Expression NCI- (Amino Acid) GRCh38 RNAseq Data 11358 DNAJB1 S186= 19:14516700- no mutation 46
[0459] 14516700
[0460] KRAS G12C 12:25245351- C~>A 72% 22.6
[0461] 25245351
[0462] TP63 V364I 3:189868677- G~> A 49% 6.5
[0463] 189868677
[0464] FGFR1 R240H 8:38426241- C->T 73% 1
[0465] 38426241
[0466] PTPRC M769K 1:198735155- T->A (1 read 0.01
[0467] 198735155 coverage)
[0468]
[0469] Table 2
[0470] Structure of linear probes:
[0471] right z; / v>Z>e=“ / 5Phos / ”+target RHS+“ ACGCGGTTAGC ACGTANNAQw.sto / / / Region}+ probeset_barcode_8nt+“CGGTCCTAGCAA” (Capture Seq)
[0472] left pro6e=SDacer+“CCTTGGCACCCGAGAATTCCA”(pR2S)+target LHS( gap at this end, this gap is the location for mutation)
[0473] • Spacer sequence = GC AACGACTCC AC ACTC ATA (SEQ ID NO : 1 )
[0474] • Constant Region= ACGCGGTTAGCACGTANN (SEQ ID NO: 2)
[0475] • Capture &?q=CGGTCCTAGCAA (SEQ ID NO : 3)
[0476] • target RHS = means the flanking region on the right side of mutation locus / target locus, its sequence is the same as the reference sequence in this region, like a PCR primer
[0477] • target LHS = means the flanking region on the left side of mutation locus / target locus, its sequence is the same as the reference sequence in this region, like a PCR primer (also referred to herein as “LFS”)
[0478] • pR2S = CCTTGGCACCCGAGAATTCCA (SEQ ID NO: 4)
[0479] Further details regarding exemplary linear probes are shown in FIG.3B.
[0480]
[0481] 516578835.1 64Attorney Ref. No. 00B206.1727
[0482] Structure of padlock probes:
[0483] padlock=right_arm+left_arm_spacer
[0484] • right arm = ‘75Phos / ”+target_RHS+ “ACGCGGTTAGCACGTANN” (Constant Aegzo«)+probeset_barcode_8nt+ “CGGTCCTAGCAA” (Capture Seq)
[0485] • left arm spacer = Spacer+ “CCTTGGCACCCGAGAATTCCA”
[0486] (pR2S)+target LHS( gap at this end, this gap is the location for mutation)
[0487] Further details regarding an exemplary padlock probe are shown in FIG. 3A.
[0488] Final sequencing library structure p7+i7+left_arm+right_arm+10xUMI+10xCellBarcode+readlseqprimer+i5+p5
[0489] Further details regarding exemplary final sequencing library structures are shown in FIGs. 3A and 3B.
[0490]
[0491] To further improve the number of false positives, a new chemistry strategy was used in the disclosed method that includes a direct gap filling chemistry for DNA padlock / linear probe binding to RNA template. An exemplary gap filling method is shown in FIG. 2, which uses reversible terminator nucleotides to fill the gap in the mutation-specific probe. As shown in FIG. 5, the data using this chemistry strategy showed excellent accuracy in mutation detection, almost eliminating the false signals. FIG. 7 shows data comparing the use of reversible terminator nucleotides for the gap filling technique (referred to as “RT Gap”) and the use of unblocked nucleotides (referred to as “DNApol”). As shown in FIG.7, the signal to noise ratio was significantly reduced using the gap filling strategy (of FIG. 2) compared to using unblocked nucleotides. Additional strategies were performed to reduce signal to noise and improve mapping rate as shown in FIG.8, which provide data comparing different crosslinking strategies (see Table 3). Improved signal to noise was shown using padlock probes with the gap filling strategy in the absence of decrosslinking.
[0492] Table 3
[0493] Conditions Probe Decrosslinking* Direct Ligation ddpadlock ori
[0494] Direct Ligation ddpadlock pk
[0495] Direct Ligation ddpadlock pkexo
[0496]
[0497] Direct Ligation ddpadlock s
[0498] 516578835.1 65Attorney Ref. No. 00B206.1727
[0499] Conditions Probe Decrosslinking* Direct Ligation linear ori
[0500] Direct Ligation linear Pk
[0501] Direct Ligation linear s
[0502] DNApol ddpadlock ori
[0503] DNApol ddpadlock Pk
[0504] DNApol ddpadlock pkexo
[0505] DNApol ddpadlock s
[0506] DNApol linear ori
[0507] DNApol linear Pk
[0508] DNApol linear s
[0509] RT Gap ddpadlock ori
[0510] RT Gap ddpadlock Pk
[0511] RT Gap ddpadlock pkexo
[0512] RT Gap ddpadlock s
[0513] RT Gap linear ori
[0514] RT Gap linear Pk
[0515]
[0516] RT Gap linear s
[0517] *Ori (no decrosslinking), pk (Proteinase K), pkexo (Proteinase K + exosome nuclease digestion), s (supernatant).
[0518] Allele drop out was further analyzed to determine accuracy of the disclosed method. As shown in FIG. 9, allele dropout was observed using padlock probes and unblocked nucleotides and was improved when using padlock probes or linear probes and the gap filling technique described herein.
[0519] As described herein, the presently disclosed method improved the specificity of hybridization and ligation by using such probes along with specific gap filling chemistry. In particular, improved specificity was observed using padlock probes, which is a unique class of probing molecules known for their high specificity and multiplexity instead of linear probes, rather than linear probes, in combination with a specific gap filling chemistry that uses reversible terminator nucleotides and ligation.
[0520] The initial focus during development of the disclosed method was on KRAS mutations, which have been well characterized in the proposed cell lines through exome sequencing, RNA sequencing, single cell gene expression and long read sequencing. However, the presently disclosed method can be further expanded to target larger genomic regions and enable the detection of insertions, deletions and fusion genes. In addition, given the similarities between the Flex Gene Expression (FRP) kit and the Viscum spatial assays, the disclosed method can
[0521] 516578835.1 66Attorney Ref. No. 00B206.1727
[0522] be used for in situ detection, thus allowing the interrogation of mutations and gene expression with single-cell and spatial resolution. This strategy can also be valuable for other advanced single cell and spatial genomics methods, including Optical Pooled Screening, lOx Genomics Visium, lOx Genomics Xenium, and spatial single cell RNA and protein profiling.
[0523] 516578835.1 67
Claims
Attorney Ref. No. 00B206.1727WHAT IS CLAIMED IS:
1. A method for generating a library comprising a variant of a target nucleic acid or for identifying a variant of a target nucleic acid, comprising:(a) providing a plurality of cells or nuclei;(b) contacting the plurality of cells or nuclei with at least one mutation-specific probe that hybridizes to a target nucleic acid, wherein the mutation-specific probe comprises a gap of at least one nucleotide and / or generates a gap of at least one nucleotide upon hybridization to the target nucleic acid; and(c) performing a gap filling process, wherein the gap filling process comprises:(i) contacting the mutation-specific probe hybridized to the target nucleic acid with reversible terminator nucleotides to incorporate a reversible terminator nucleotide comprising a blocking group into the gap of the mutation-specific probe or the gap generated by hybridization of the mutation-specific probe to the target nucleic acid;(ii) removing the blocking group from the reversible terminator nucleotide incorporated into the mutation-specific probe; and(iii) ligating the mutation-specific probe to generate a gap filled mutationspecific probe.
2. The method of claim 1 further comprising generating a target nucleic acid-specific library comprising the sequence of the gap filled mutation specific probe or the sequence complementary to the gap filled mutation specific probe.
3. A method for generating a library comprising a variant of a target nucleic acid, comprising:(a) providing a plurality of cells or nuclei;(b) contacting the plurality of cells or nuclei with at least one mutation-specific probe that hybridizes to a target nucleic acid, wherein the mutation-specific probe comprises a gap of at least one nucleotide and / or generates a gap of at least one nucleotide upon hybridization to the target nucleic acid;(c) performing a gap filling process, wherein the gap filling process comprises:(i) contacting the mutation-specific probe hybridized to the target nucleic acid516578835.1 68Attorney Ref. No. 00B206.1727with reversible terminator nucleotides to incorporate a reversible terminator nucleotide comprising a blocking group into the gap of the mutation-specific probe or the gap generated by hybridization of the mutation-specific probe to the target nucleic acid;(ii) removing the blocking group from the reversible terminator nucleotide incorporated into the mutation-specific probe; and(iii) ligating the mutation-specific probe to generate a gap filled mutationspecific probe;(d) contacting the cells or nuclei comprising the gap filled mutation-specific probes with a plurality of particles, wherein each of the particles is coupled to a polynucleotide comprising a barcode;(e) partitioning individual particles of the plurality of particles and the cells or nuclei comprising the gap filled mutation-specific probes into compartments;(f) incorporating the barcode of the polynucleotide into the gap filled mutationspecific probes to generate barcoded target nucleic acids;(g) combining all or a subset of the barcoded target nucleic acids to generate pooled barcoded nucleic acids; and(i) generating a target nucleic acid-specific library comprising the barcoded transcript-specific nucleic acids from the pooled barcoded nucleic acids.
4. A method for generating a library comprising a variant of a target nucleic acid, comprising:(a) providing a plurality of cells or nuclei;(b) contacting the plurality of cells or nuclei with at least one mutation-specific probe that hybridizes to a target nucleic acid, wherein the mutation-specific probe comprises a gap of at least one nucleotide and / or generates a gap of at least one nucleotide upon hybridization to the target nucleic acid;(c) performing a gap filling process, wherein the gap filling process comprises:(i) contacting the mutation-specific probe hybridized to the target nucleic acid with reversible terminator nucleotides to incorporate a reversible terminator nucleotide comprising a blocking group into the gap of the mutation-specific probe or the gap generated by hybridization of the mutation-specific probe to the target nucleic acid;516578835.1 69Attorney Ref. No. 00B206.1727(ii) removing the blocking group from the reversible terminator nucleotide incorporated into the mutation-specific probe; and(iii) ligating the mutation-specific probe to generate a gap filled mutationspecific probe;(d) contacting the cells or nuclei comprising the gap filled mutation-specific probes with a plurality of transcriptome-specific probes;(e) contacting the cells or nuclei comprising the gap filled mutation-specific probes and the transcriptome-specific probes with a plurality of particles, wherein each of the particles is coupled to a polynucleotide comprising a barcode;(f) partitioning individual particles of the plurality of particles and the cells or nuclei comprising the gap filled mutation-specific probes and the transcriptome-specific probes into compartments;(g) incorporating the barcode of the polynucleotide into the gap filled mutationspecific probes to generate barcoded target nucleic acids and incorporating the barcode of the polynucleotide into the transcriptome-specific probes to generate barcoded transcript-specific nucleic acids in the compartments, wherein the barcode of the barcoded target nucleic acids and the barcode of the barcoded transcript-specific nucleic acids present in a single compartment comprise the same nucleotide sequence;(h) combining all or a subset of the barcoded target nucleic acids and the barcoded transcript-specific nucleic acids from the compartments to generate pooled barcoded nucleic acids; and(i) generating a target nucleic acid-specific library comprising the barcoded transcript-specific nucleic acids from the pooled barcoded nucleic acids.
5. The method of claim 3 or 4 further comprising sequencing all or a subset of the barcoded target nucleic acids in the target nucleic acid-specific library to identify one or more variants of the target nucleic acids.
6. The method of claim 4 further comprising generating a transcript-specific library comprising the barcoded transcript-specific nucleic acids from the pooled barcoded nucleic acids.516578835.1 70Attorney Ref. No. 00B206.17277. The method of claim 5 further comprising sequencing all or a subset of the barcoded transcript-specific nucleic acids in the target nucleic acid-specific library.
8. A method for identifying a variant of a target nucleic acid, comprising:(a) providing a plurality of cells or nuclei;(b) contacting the plurality of cells or nuclei with at least one mutation-specific probe that hybridizes to a target nucleic acid, wherein the mutation-specific probe comprises a gap of at least one nucleotide and / or generates a gap of at least one nucleotide upon hybridization to the target nucleic acid;(c) performing a gap filling process, wherein the gap filling process comprises:(i) contacting the mutation-specific probe hybridized to the target nucleic acid with reversible terminator nucleotides to incorporate a reversible terminator nucleotide comprising a blocking group into the gap of the mutation-specific probe or the gap generated by hybridization of the mutation-specific probe to the target nucleic acid;(ii) removing the blocking group from the reversible terminator nucleotide incorporated into the mutation-specific probe; and(iii) ligating the mutation-specific probe to generate a gap filled mutationspecific probe;(d) contacting the cells or nuclei comprising the gap filled mutation-specific probes, wherein each of the particles is coupled to a polynucleotide comprising a barcode;(e) partitioning individual particles of the plurality of particles and the cells or nuclei comprising the gap filled mutation-specific probes into compartments;(f) incorporating the barcode of the polynucleotide into the gap filled mutationspecific probes to generate barcoded target nucleic acids;(g) combining all or a subset of the barcoded target nucleic acids to generate pooled barcoded nucleic acids;(i) generating a target nucleic acid-specific library comprising the barcoded transcript-specific nucleic acids from the pooled barcoded nucleic acids; and(j) sequencing all or a subset of the barcoded target nucleic acids in the library to identify one or more variants of the target nucleic acids.
9. A method for identifying a variant of a target nucleic acid, comprising:516578835.1 71Attorney Ref. No. 00B206.1727(a) providing a plurality of cells or nuclei;(b) contacting the plurality of cells or nuclei with at least one mutation-specific probe that hybridizes to a target nucleic acid, wherein the mutation-specific probe comprises a gap of at least one nucleotide and / or generates a gap of at least one nucleotide upon hybridization to the target nucleic acid;(c) performing a gap filling process, wherein the gap filling process comprises:(i) contacting the mutation-specific probe hybridized to the target nucleic acid with reversible terminator nucleotides to incorporate a reversible terminator nucleotide comprising a blocking group into the gap of the mutation-specific probe or the gap generated by hybridization of the mutation-specific probe to the target nucleic acid;(ii) removing the blocking group from the reversible terminator nucleotide incorporated into the mutation-specific probe; and(iii) ligating the mutation-specific probe to generate a gap filled mutationspecific probe;(d) contacting the cells or nucleic comprising the gap filled mutation-specific probes with a plurality of transcriptome-specific probes;(e) contacting the cells or nuclei comprising the gap filled mutation-specific probes and the transcriptome-specific probes with a plurality of particles, wherein each of the particles is coupled to a polynucleotide comprising a barcode;(f) partitioning individual particles of the plurality of particles and the cells or nuclei comprising the gap filled mutation-specific probes and the transcriptome-specific probes into compartments;(g) incorporating the barcode of the polynucleotide into the gap filled mutationspecific probes to generate barcoded target nucleic acids and incorporating the barcode of the polynucleotide into the transcriptome-specific probes to generate barcoded transcript-specific nucleic acids in the compartments, wherein the barcode of the barcoded target nucleic acids and the barcode of the barcoded transcript-specific nucleic acids present in a single compartment comprise the same nucleotide sequence;(h) combining all or a subset of the barcoded target nucleic acids and the barcoded transcript-specific nucleic acids from the compartments to generate pooled barcoded nucleic acids;516578835.1 72Attorney Ref. No. 00B206.1727(i) generating a target nucleic acid-specific library comprising the barcoded target nucleic acids from the pooled barcoded nucleic acids;(j) generating a transcript-specific library comprising the barcoded transcriptspecific nucleic acids from the pooled barcoded nucleic acids; and(k) sequencing all or a subset of the barcoded target nucleic acids in the library to identify one or more variants of the target nucleic acids.
10. The method of claim 9 further comprising sequencing all or a subset of the barcoded transcript-specific nucleic acids in the library to identify transcript-specific nucleic acids.
11. The method of claim 9 or 10 further comprising comparing the barcoded target nucleic acids to the transcript-specific nucleic acids in a single cell.
12. The method of any one of claims 3-11, wherein the generation of a library comprising the barcoded target nucleic acids comprises (i) amplifying the barcoded target nucleic acids by contacting the pool of barcoded nucleic acids with one or more primers coupled to a label to generate amplified barcoded target nucleic acids coupled to the label, wherein the one or more primers specifically hybridize to the barcoded target nucleic acids and (ii) isolating the amplified target nucleic acids coupled to the label to generate the library.
13. The method of claim 12, wherein the label comprises biotin.
14. The method of claim 12 or 13, wherein isolating the amplified target nucleic acids coupled to the label comprises contacting the sample with an agent that binds to the label.
15. The method of claim 14, wherein the agent comprises streptavidin.
16. The method of any one of claims 1-15, wherein the gap of at least one nucleotide corresponds to at least one nucleotide that is variant in the target nucleic acid compared to a reference sequence.
17. The method of any one of claims 1-16, wherein the mutation-specific probes are padlock probes.
18. The method of claim 17, wherein the padlock probes comprise a first homology region that is complementary to a first sequence of the target nucleic acid and a second homology region that is complementary to a second sequence of the target nucleic acid, and wherein the gap of at least one nucleotide is located between the first homology region and the second516578835.1 73Attorney Ref. No. 00B206.1727homology region.
19. The method of any one of claims 1-16, wherein the mutation-specific probes comprise a pair of linear probes.
20. The method of claim 19, wherein one probe of the pair of linear probes comprises a first homology region that is complementary to a first sequence of the target nucleic acid and the second probe of the pair of linear probes comprises a second homology region that is complementary to a second sequence of the target nucleic acid, and wherein the gap of at least one nucleotide is located between the first homology region and the second homology region.
21. The method of any one of claims 1-20, wherein the gap of at least one nucleotide corresponds to the nucleotides that are variant in the target nucleic acid.
22. The method of any one of claims 1-21, wherein the mutation-specific probes and / or the transcriptome-specific probes comprise one or more of the following: (a) constant region sequence, (b) a spacer sequence and (c) a capture sequence.
23. The method of claim 22, wherein the constant region sequence, the spacer sequence or the capture sequence comprises a primer binding nucleotide sequence for use in amplifying the barcoded target nucleic acids.
24. The method of claim 22 or 23, wherein the polynucleotides comprising the barcode further comprises a sequence that hybridizes to the capture sequence of the mutation-specific probes and / or the transcriptome-specific probes.
25. The method of any one of claims 1 -24, wherein the plurality of cells or nuclei are treated with a fixative prior to step (a).
26. The method of any one of claims 1-25, wherein the plurality of cells is permeabilized or lysed prior to step (a).
27. The method of any one of claims 1-26, wherein the compartments are emulsion droplets.
28. The method of claim 27, wherein the emulsion droplets are generated in an emulsion droplet generating device or generated using an emulsion droplet generating technique.
29. The method of any one of claims 1-28, wherein the target nucleic acid comprises RNA.516578835.1 74Attorney Ref. No. 00B206.172730. The method of any one of claims 1-28, wherein the target nucleic acid comprises DNA.
31. The method of any one of claims 1-30, wherein the plurality of cells comprises cancer cells.
32. The method of any one of claims 1-31 for use in identifying a variant of a target nucleic acid in a sample from a subject.
33. The method of any one of claims 1-32 for use diagnosing a disease in a subject.
34. The method of any one of claims 1-33 for use diagnosing a cancer in a subject.
35. A mutation-specific probe comprising:(a) a left homology site comprising a sequence that is complementary to a first sequence of a target nucleic acid;(b) a spacer sequence;(c) a capture sequence;(d) a probe barcode sequence;(e) a constant region; and(f) a right homology site comprising a sequence that is complementary to a sequence of the target nucleic acid,(g) wherein the mutation-specific probe comprises a gap of at least one nucleotide and / or generates a gap of at least one nucleotide upon hybridization of the left homology site and the right homology site to the target nucleic acid, and(h) wherein the gap corresponds to or includes the variant sequence in the target nucleic acid.
36. The mutation-specific probe of claim 35, wherein:(i) the spacer sequence comprises a nucleotide sequence that has about 75%, about 80%, about 85%, about 90%, about 95%, about 96%, about 97%, about 98%, about 99% or about 100% homology to SEQ ID NO: 1;516578835.1 75Attorney Ref. No. 00B206.1727(ii) the capture sequence comprises a nucleotide sequence that has about 75%, about 80%, about 85%, about 90%, about 95%, about 96%, about 97%, about 98%, about 99% or about 100% homology to SEQ ID NO: 3; and / or(iii) the constant region comprises a nucleotide sequence that has about 75%, about 80%, about 85%, about 90%, about 95%, about 96%, about 97%, about 98%, about 99% or about 100% homology to SEQ ID NO: 2.
37. A kit for performing the method of any one of claims 1-34.
38. The kit of claim 37 comprising the mutation-specific probe of claim 35 or 36.
39. A system for performing the method of any one of claims 1-34.
40. The system of claim 39 comprising the mutation-specific probe of claim 35 or 36.516578835.1 76
